NO132865B - - Google Patents
Download PDFInfo
- Publication number
- NO132865B NO132865B NO3712/70A NO371270A NO132865B NO 132865 B NO132865 B NO 132865B NO 3712/70 A NO3712/70 A NO 3712/70A NO 371270 A NO371270 A NO 371270A NO 132865 B NO132865 B NO 132865B
- Authority
- NO
- Norway
- Prior art keywords
- methyl
- methylthiophenyl
- ether
- formula
- production
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 36
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 26
- 150000001412 amines Chemical class 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 20
- -1 1-(3-methyl-4-isopropylthiophenyl)-2-n-octylaminopropanol Chemical compound 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 230000009467 reduction Effects 0.000 claims description 15
- 150000001414 amino alcohols Chemical class 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 13
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 11
- SNTAMUYOZKRZON-UHFFFAOYSA-N 1-(3,4-dimethylthiophen-2-yl)-2-(propan-2-ylamino)ethanol Chemical compound CC(C)NCC(O)C=1SC=C(C)C=1C SNTAMUYOZKRZON-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- BFCDFTHTSVTWOG-UHFFFAOYSA-N 2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol Chemical compound CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1 BFCDFTHTSVTWOG-UHFFFAOYSA-N 0.000 claims description 7
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 4
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- UEYDIPLYIDOLKX-UHFFFAOYSA-N 2-(3,4-dimethylthiophen-2-yl)oxirane Chemical compound CC1=CSC(C2OC2)=C1C UEYDIPLYIDOLKX-UHFFFAOYSA-N 0.000 claims description 3
- SIIBRCVEMXCIFT-UHFFFAOYSA-N 2-amino-1-(3,4-dimethylthiophen-2-yl)ethanol Chemical compound CC1=CSC(C(O)CN)=C1C SIIBRCVEMXCIFT-UHFFFAOYSA-N 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 239000003638 chemical reducing agent Substances 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- PZAAIKOEKCIJSJ-UHFFFAOYSA-N 1-(3,4-dimethylthiophen-2-yl)-2-(octylamino)ethanol Chemical compound CCCCCCCCNCC(O)C=1SC=C(C)C=1C PZAAIKOEKCIJSJ-UHFFFAOYSA-N 0.000 claims 1
- USQMAOKKWZXQJG-UHFFFAOYSA-N 1-(4-ethylsulfanylphenyl)-2-(octylamino)propan-1-ol Chemical compound CCCCCCCCNC(C)C(O)C1=CC=C(SCC)C=C1 USQMAOKKWZXQJG-UHFFFAOYSA-N 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 160
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 114
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 77
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 71
- 239000000243 solution Substances 0.000 description 62
- 239000000047 product Substances 0.000 description 58
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 50
- 239000002904 solvent Substances 0.000 description 48
- 239000000203 mixture Substances 0.000 description 38
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 32
- 239000013256 coordination polymer Substances 0.000 description 29
- 230000000694 effects Effects 0.000 description 29
- 235000019441 ethanol Nutrition 0.000 description 25
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 25
- 235000019341 magnesium sulphate Nutrition 0.000 description 25
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 24
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 24
- 238000003756 stirring Methods 0.000 description 24
- 239000012074 organic phase Substances 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- 239000012279 sodium borohydride Substances 0.000 description 18
- 229910000033 sodium borohydride Inorganic materials 0.000 description 18
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 16
- 239000007789 gas Substances 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 16
- 238000002844 melting Methods 0.000 description 15
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 14
- 238000006722 reduction reaction Methods 0.000 description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 13
- 230000008018 melting Effects 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- BFCDFTHTSVTWOG-PXNSSMCTSA-N (1r,2s)-2-(octylamino)-1-(4-propan-2-ylsulfanylphenyl)propan-1-ol Chemical compound CCCCCCCCN[C@@H](C)[C@H](O)C1=CC=C(SC(C)C)C=C1 BFCDFTHTSVTWOG-PXNSSMCTSA-N 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 8
- 229960001789 papaverine Drugs 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- 230000002921 anti-spasmodic effect Effects 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 229910052794 bromium Inorganic materials 0.000 description 7
- 230000002057 chronotropic effect Effects 0.000 description 7
- 229960002748 norepinephrine Drugs 0.000 description 7
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 7
- 150000002924 oxiranes Chemical class 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- FPMHBZXISVCNQY-UHFFFAOYSA-N 1-(3-methyl-4-methylsulfanylphenyl)-2-(octylamino)ethanol Chemical compound CCCCCCCCNCC(O)C1=CC=C(SC)C(C)=C1 FPMHBZXISVCNQY-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 6
- 239000012346 acetyl chloride Substances 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000031709 bromination Effects 0.000 description 6
- 238000005893 bromination reaction Methods 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- IRRHYISQEMIMQS-UHFFFAOYSA-N 1-(3,4-dimethylthiophen-2-yl)-2-(propan-2-ylamino)ethanol;hydrochloride Chemical compound Cl.CC(C)NCC(O)C=1SC=C(C)C=1C IRRHYISQEMIMQS-UHFFFAOYSA-N 0.000 description 5
- 230000001800 adrenalinergic effect Effects 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000000304 vasodilatating effect Effects 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 4
- 150000008046 alkali metal hydrides Chemical class 0.000 description 4
- SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- JGYXEYQQCOUEOV-UHFFFAOYSA-N 2-bromo-1-(3,4-dimethylthiophen-2-yl)ethanol Chemical compound CC1=CSC(C(O)CBr)=C1C JGYXEYQQCOUEOV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 150000003935 benzaldehydes Chemical class 0.000 description 3
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 229910003446 platinum oxide Inorganic materials 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- BHRZNVHARXXAHW-UHFFFAOYSA-N sec-butylamine Chemical compound CCC(C)N BHRZNVHARXXAHW-UHFFFAOYSA-N 0.000 description 3
- 239000003506 spasmogen Substances 0.000 description 3
- CKMBUVYERYFPBD-UHFFFAOYSA-N 1-(3-methyl-4-methylsulfonylphenyl)-2-(propan-2-ylamino)ethanol Chemical compound CC(C)NCC(O)C1=CC=C(S(C)(=O)=O)C(C)=C1 CKMBUVYERYFPBD-UHFFFAOYSA-N 0.000 description 2
- MESAAUXJNSZIAX-UHFFFAOYSA-N 1-(4-butylsulfanyl-3-methylphenyl)-2-(cyclohexylamino)ethanol Chemical compound C1=C(C)C(SCCCC)=CC=C1C(O)CNC1CCCCC1 MESAAUXJNSZIAX-UHFFFAOYSA-N 0.000 description 2
- RCTAIAKVFGOWHD-UHFFFAOYSA-N 1-(4-butylsulfanyl-3-methylphenyl)-2-piperidin-1-ylethanol Chemical compound C1=C(C)C(SCCCC)=CC=C1C(O)CN1CCCCC1 RCTAIAKVFGOWHD-UHFFFAOYSA-N 0.000 description 2
- ZUYWFUUNQDJUKG-UHFFFAOYSA-N 1-(butylamino)ethanol Chemical compound CCCCNC(C)O ZUYWFUUNQDJUKG-UHFFFAOYSA-N 0.000 description 2
- BHWJMPDCCDMCKC-UHFFFAOYSA-N 1-methyl-2-methylsulfanylbenzene Chemical compound CSC1=CC=CC=C1C BHWJMPDCCDMCKC-UHFFFAOYSA-N 0.000 description 2
- VVONJBDNSJEBGD-UHFFFAOYSA-N 2-(3-chloro-4-methylsulfanylphenyl)-2-oxoacetaldehyde Chemical compound CSC1=CC=C(C(=O)C=O)C=C1Cl VVONJBDNSJEBGD-UHFFFAOYSA-N 0.000 description 2
- GDOFZKYSOHFIFR-UHFFFAOYSA-N 2-(3-ethyl-4-methylsulfanylphenyl)-2-oxoacetaldehyde Chemical compound CCC1=CC(C(=O)C=O)=CC=C1SC GDOFZKYSOHFIFR-UHFFFAOYSA-N 0.000 description 2
- AZUSBMRBGKXNHN-UHFFFAOYSA-N 2-(3-methyl-4-propan-2-ylsulfanylphenyl)-2-oxoacetaldehyde Chemical compound CC(C)SC1=CC=C(C(=O)C=O)C=C1C AZUSBMRBGKXNHN-UHFFFAOYSA-N 0.000 description 2
- BICUHBNZUVPILE-UHFFFAOYSA-N 2-bromo-1-(3-chloro-4-methylsulfanylphenyl)ethanol Chemical compound CSC1=CC=C(C(O)CBr)C=C1Cl BICUHBNZUVPILE-UHFFFAOYSA-N 0.000 description 2
- ZEPXIZHSGCGQSM-UHFFFAOYSA-N 2-bromo-1-(4-ethylsulfanyl-3-methylphenyl)ethanol Chemical compound CCSC1=CC=C(C(O)CBr)C=C1C ZEPXIZHSGCGQSM-UHFFFAOYSA-N 0.000 description 2
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N 3-Methylbutan-2-one Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000000538 analytical sample Substances 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 239000004312 hexamethylene tetramine Substances 0.000 description 2
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 description 2
- 229910000103 lithium hydride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229960004011 methenamine Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 230000003033 spasmogenic effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- DYWNLSQWJMTVGJ-UHFFFAOYSA-N (1-hydroxy-1-phenylpropan-2-yl)azanium;chloride Chemical compound Cl.CC(N)C(O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-UHFFFAOYSA-N 0.000 description 1
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- ILAPJVHMNUWOTG-UHFFFAOYSA-N 1-(3,4-dimethylthiophen-2-yl)-2-(3-methylbutan-2-ylamino)ethanol hydrochloride Chemical compound Cl.CC1=C(SC=C1C)C(CNC(C(C)C)C)O ILAPJVHMNUWOTG-UHFFFAOYSA-N 0.000 description 1
- CPINTLRIVKDDLW-UHFFFAOYSA-N 1-(3,4-dimethylthiophen-2-yl)-2-(propan-2-ylamino)ethanol;oxalic acid Chemical compound OC(=O)C(O)=O.CC(C)NCC(O)C=1SC=C(C)C=1C CPINTLRIVKDDLW-UHFFFAOYSA-N 0.000 description 1
- HFSPSTCBDRGIFB-UHFFFAOYSA-N 1-(3-chloro-4-methylsulfanylphenyl)-2-(propan-2-ylamino)ethanol Chemical compound CSC1=CC=C(C(O)CNC(C)C)C=C1Cl HFSPSTCBDRGIFB-UHFFFAOYSA-N 0.000 description 1
- IINKMZCSMKVAAK-UHFFFAOYSA-N 1-(3-chloro-4-methylsulfanylphenyl)-2-(propan-2-ylamino)ethanol;hydrochloride Chemical compound Cl.CSC1=CC=C(C(O)CNC(C)C)C=C1Cl IINKMZCSMKVAAK-UHFFFAOYSA-N 0.000 description 1
- ZXXVDHJMSUIZCI-UHFFFAOYSA-N 1-(3-ethyl-4-methylsulfanylphenyl)-2-(propan-2-ylamino)ethanol Chemical compound CCC1=CC(C(O)CNC(C)C)=CC=C1SC ZXXVDHJMSUIZCI-UHFFFAOYSA-N 0.000 description 1
- WQAROSMHVMXNHM-UHFFFAOYSA-N 1-(4-butylsulfanyl-3-methylphenyl)-2-(3-methoxypropylamino)ethanol Chemical compound CCCCSC1=CC=C(C(O)CNCCCOC)C=C1C WQAROSMHVMXNHM-UHFFFAOYSA-N 0.000 description 1
- OJZPXXITDUHENJ-UHFFFAOYSA-N 1-(4-ethylsulfanylphenyl)-2-(octylamino)propan-1-ol;hydrochloride Chemical compound Cl.CCCCCCCCNC(C)C(O)C1=CC=C(SCC)C=C1 OJZPXXITDUHENJ-UHFFFAOYSA-N 0.000 description 1
- WNGLRAPNRFQYBW-UHFFFAOYSA-N 1-(4-methylsulfanylphenyl)-2-(octylamino)propan-1-ol Chemical compound CCCCCCCCNC(C)C(O)C1=CC=C(SC)C=C1 WNGLRAPNRFQYBW-UHFFFAOYSA-N 0.000 description 1
- FZXCBSDWXUQZBL-UHFFFAOYSA-N 1-(4-methylsulfanylphenyl)-2-(propan-2-ylamino)ethanol Chemical compound CSC1=CC=C(C=C1)C(CNC(C)C)O FZXCBSDWXUQZBL-UHFFFAOYSA-N 0.000 description 1
- AUXBHTYZRWYEPL-UHFFFAOYSA-N 1-(butylamino)ethanol;hydrochloride Chemical compound Cl.CCCCNC(C)O AUXBHTYZRWYEPL-UHFFFAOYSA-N 0.000 description 1
- RNLYLNHPQLCRFI-UHFFFAOYSA-N 1-butylsulfanyl-2-methylbenzene Chemical compound CCCCSC1=CC=CC=C1C RNLYLNHPQLCRFI-UHFFFAOYSA-N 0.000 description 1
- IHLDFHCSSCVPQW-UHFFFAOYSA-N 1-chloro-2-methylsulfanylbenzene Chemical compound CSC1=CC=CC=C1Cl IHLDFHCSSCVPQW-UHFFFAOYSA-N 0.000 description 1
- QDKADVFXVVXZKV-UHFFFAOYSA-N 2-(3,4-dimethylthiophen-2-yl)-2-oxoacetaldehyde Chemical compound CC1=CSC(C(=O)C=O)=C1C QDKADVFXVVXZKV-UHFFFAOYSA-N 0.000 description 1
- MGOZYPBULGKQDZ-UHFFFAOYSA-N 2-(3-methoxy-4-methylsulfanylphenyl)-2-oxoacetaldehyde Chemical compound COC1=CC(C(=O)C=O)=CC=C1SC MGOZYPBULGKQDZ-UHFFFAOYSA-N 0.000 description 1
- VAAXNBNXLUMKSQ-UHFFFAOYSA-N 2-(3-methyl-4-methylsulfonylphenyl)-2-oxoacetaldehyde Chemical compound CC1=CC(C(=O)C=O)=CC=C1S(C)(=O)=O VAAXNBNXLUMKSQ-UHFFFAOYSA-N 0.000 description 1
- ULEGBDOMLSYPAR-UHFFFAOYSA-N 2-(4-butylsulfanyl-3-methylphenyl)-2-oxoacetaldehyde Chemical compound CCCCSC1=CC=C(C(=O)C=O)C=C1C ULEGBDOMLSYPAR-UHFFFAOYSA-N 0.000 description 1
- PGCBCSVFFGVLTD-UHFFFAOYSA-N 2-(cyclopentylamino)-1-(4-ethylsulfanyl-3-methylphenyl)ethanol;hydrochloride Chemical compound Cl.C1=C(C)C(SCC)=CC=C1C(O)CNC1CCCC1 PGCBCSVFFGVLTD-UHFFFAOYSA-N 0.000 description 1
- UBDDCFXIKHUNRI-UHFFFAOYSA-N 2-(tert-butylamino)-1-(3,4-dimethylthiophen-2-yl)butan-1-ol Chemical compound CC(C)(C)NC(CC)C(O)C=1SC=C(C)C=1C UBDDCFXIKHUNRI-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- HMXRNSGZBYCKJA-UHFFFAOYSA-N 2-[4-(3-propan-2-ylthiophen-2-yl)octylamino]propan-1-ol;hydrochloride Chemical compound Cl.OCC(C)NCCCC(CCCC)C=1SC=CC=1C(C)C HMXRNSGZBYCKJA-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FAXDZWQIWUSWJH-UHFFFAOYSA-N 3-methoxypropan-1-amine Chemical compound COCCCN FAXDZWQIWUSWJH-UHFFFAOYSA-N 0.000 description 1
- PEORDRLTYAXAJU-UHFFFAOYSA-N 3-methyl-1-phenylpentane-1-thione Chemical compound CCC(C)CC(=S)C1=CC=CC=C1 PEORDRLTYAXAJU-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ABGXADJDTPFFSZ-UHFFFAOYSA-N 4-benzylpiperidine Chemical compound C=1C=CC=CC=1CC1CCNCC1 ABGXADJDTPFFSZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical class OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010058842 Cerebrovascular insufficiency Diseases 0.000 description 1
- CKDWIHIVRZFLDR-UHFFFAOYSA-N Cl.C(C)(C)(C)NC(C)O Chemical compound Cl.C(C)(C)(C)NC(C)O CKDWIHIVRZFLDR-UHFFFAOYSA-N 0.000 description 1
- QASBRDRSCVFCME-UHFFFAOYSA-N Cl.CS(=O)(=O)C1=CC=C(C=C1)C(CNC(C)C)O Chemical compound Cl.CS(=O)(=O)C1=CC=C(C=C1)C(CNC(C)C)O QASBRDRSCVFCME-UHFFFAOYSA-N 0.000 description 1
- BHGPJGZGXVCTHN-UHFFFAOYSA-N Cl.CSC1=CC=C(C=C1)C(CNC(C)C)O Chemical compound Cl.CSC1=CC=C(C=C1)C(CNC(C)C)O BHGPJGZGXVCTHN-UHFFFAOYSA-N 0.000 description 1
- 238000006969 Curtius rearrangement reaction Methods 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 238000003309 Hoesch reaction Methods 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010062119 Sympathomimetic effect Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Chemical class CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000008062 acetophenones Chemical class 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229960003116 amyl nitrite Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000002959 anti-hypotensive effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RTEXIPZMMDUXMR-UHFFFAOYSA-N benzene;ethyl acetate Chemical compound CCOC(C)=O.C1=CC=CC=C1 RTEXIPZMMDUXMR-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 150000005524 benzylchlorides Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MDHYEMXUFSJLGV-UHFFFAOYSA-N beta-phenethyl acetate Natural products CC(=O)OCCC1=CC=CC=C1 MDHYEMXUFSJLGV-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- GZRYBYIBLHMWCD-UHFFFAOYSA-N dimethyl(methylidene)-$l^{4}-sulfane Chemical compound CS(C)=C GZRYBYIBLHMWCD-UHFFFAOYSA-N 0.000 description 1
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- JRJJHIUHSILDOH-UHFFFAOYSA-N hydron;2-(octylamino)-1-(4-propan-2-ylsulfanylphenyl)propan-1-ol;chloride Chemical compound Cl.CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1 JRJJHIUHSILDOH-UHFFFAOYSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- CPQDZXPLQXZJGF-UHFFFAOYSA-N methyl 2-methylsulfanylbenzoate Chemical compound COC(=O)C1=CC=CC=C1SC CPQDZXPLQXZJGF-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 125000004971 nitroalkyl group Chemical group 0.000 description 1
- MCSAJNNLRCFZED-UHFFFAOYSA-N nitroethane Chemical compound CC[N+]([O-])=O MCSAJNNLRCFZED-UHFFFAOYSA-N 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 150000004885 piperazines Chemical group 0.000 description 1
- ROFVJSWBDQUQGW-UHFFFAOYSA-N piperidin-1-ium;bromide Chemical compound Br.C1CCNCC1 ROFVJSWBDQUQGW-UHFFFAOYSA-N 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- SNOAHAUUBQMVGW-UHFFFAOYSA-N propan-2-ylsulfanylbenzene Chemical compound CC(C)SC1=CC=CC=C1 SNOAHAUUBQMVGW-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- KRIOVPPHQSLHCZ-UHFFFAOYSA-N propiophenone Chemical class CCC(=O)C1=CC=CC=C1 KRIOVPPHQSLHCZ-UHFFFAOYSA-N 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- CQKAPARXKPTKBK-UHFFFAOYSA-N tert-butylazanium;bromide Chemical compound Br.CC(C)(C)N CQKAPARXKPTKBK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/34—Compounds containing oxirane rings with hydrocarbon radicals, substituted by sulphur, selenium or tellurium atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Denne oppfinnelsen vedrorer en analogifremgangsmåte for fremstillingen .av nye, terapeutisk aktive aminoalkoholer og salter herav. This invention relates to an analogous process for the production of new, therapeutically active amino alcohols and salts thereof.
De nye amino-alkoholene fremstilt ifolge oppfinnelsen re-presenteres av formelen The new amino alcohols produced according to the invention are represented by the formula
hvor betyr RS eller RS02, hvor where means RS or RS02, where
R er en rett eller forgrenet C^-C^Qalkylgruppe, og R is a straight or branched C 1 -C 4 alkyl group, and
hvor R2 og R^ er forskjellige og betyr hydrogen, halogen, en C^- C^ alkyl-, C^- C^ karbalkoksy- eller C^-C^ alkoksygruppe, where R2 and R^ are different and mean hydrogen, halogen, a C^-C^ alkyl-, C^-C^ carbolic- or C^-C^ alkoxy group,
R^ betyr hydrogen eller en rett eller forgrenet C^- R^ means hydrogen or a straight or branched C^-
C 4 alkylgruppe, C 4 alkyl group,
R^ og R^, som kan være like eller forskjellige, betyr hydrogen, en rett eller forgrenet C-^-Cj^q alkyl-, en C5-C6 cykloalkyl-, en C-j-C4 alkenyl-, eller en eventuelt med ett eller flere kloratomer eller hydroksylgrupper substituert C^-c5 alkylfenylgruppe, eller R^ og Rg kan sammen med det tilstotende nitrogenatom danne en eventuelt med en C^-C^ alkyl-, benzyl-, eller hydroksylgruppe substituert piperdinring, en morfolin-ring, en eventuelt med en C^-C^ alkylfenylgruppe substituert piperazinring eller en 3-azabicyklo [3.2.1.]-oktylring, og når R^ betegner hydrogen og R& en C4-C10 alkylgruppe, kan R2 og R3 begge være hydrogen eller metylgruppér, R^ and R^, which may be the same or different, mean hydrogen, a straight or branched C-^-Cj^q alkyl-, a C5-C6 cycloalkyl-, a C-j-C4 alkenyl-, or an optionally with one or several chlorine atoms or hydroxyl groups substituted with a C^-C5 alkylphenyl group, or R^ and Rg can together with the adjacent nitrogen atom form a piperidine ring optionally substituted with a C^-C^ alkyl, benzyl, or hydroxyl group, a morpholine ring, an optionally with a C^-C^ alkylphenyl group substituted piperazine ring or a 3-azabicyclo [3.2.1.]-octyl ring, and when R^ denotes hydrogen and R& a C4-C10 alkyl group, R2 and R3 can both be hydrogen or methyl groups,
såvel som salter av disse forbindelser. as well as salts of these compounds.
Amino-alkoholer som omfattes av den nevnte formel I er senere omtalt i eksemplene og fSigende "amino-alkoholer er av spesiell interesse på grunn av deres gunstige effekt. Amino-alcohols covered by the aforementioned formula I are discussed later in the examples and fSaid "amino-alcohols are of particular interest because of their beneficial effect.
1-(2-klor-4-metyltiofenyl)-2-N-piperidinoetanol-hydroklorid, 1-(3-klor-4-metyltiofenyl)-2-sek.butylaminopentanol-hydrbklorid, 1- (3-metyl-4-isopropyltiofenyl)-2-n-oktylaminopropanol-hydroklorid, 1- (4-isopropyltiofenyl)-2-n-oktylaminopropanol, 1-(2-chloro-4-methylthiophenyl)-2-N-piperidinoethanol hydrochloride, 1-(3-chloro-4-methylthiophenyl)-2-sec.butylaminopentanol hydrochloride, 1-(3-methyl-4-isopropylthiophenyl )-2-n-octylaminopropanol hydrochloride, 1-(4-isopropylthiophenyl)-2-n-octylaminopropanol,
1-(3-metyl-4-nætyltiofenyl)-2-n-oktylaminoetanol-hydroklorid, 1- (4-etyltiofenyl)-2-n-oktylaminopropanol-hydroklorid, 1-(3-methyl-4-nethylthiophenyl)-2-n-octylaminoethanol hydrochloride, 1-(4-ethylthiophenyl)-2-n-octylaminopropanol hydrochloride,
1-(3-metyl-4-metyltiofenyl)-2-isopropylaminoetanol-hydroklorid. 1-(3-methyl-4-methylthiophenyl)-2-isopropylaminoethanol hydrochloride.
Noen amino-alkoholer er allerede tidligere kjent og er beskrevet i de fSigende publikasjoner: 1. Nederlandsk patentsøknad nr. 67/0984, tilsvarende fransk patent nr. 1.573.832 (Pratesi, Villa, Grana) 2. Farmaco Edizione Scientifica, vol.24 (3), sidene 329-340 (1969) 3. Farmaco Edizione Scientifica, vol.22(8), sidene 573-581 (1967) (Chemical Abstracts, vol. 67, 80849 - 1967) 4. Fransk patent nr. 1.503.517 (Bayer), tilsvarende U.S. patent nr. 3.334.188 (Wollweber) 5. Osterriksk patent nr. 252.215 (P.Somani, J. Med. Chem. 9, 823 - 1966) Some amino alcohols are already previously known and are described in the following publications: 1. Dutch patent application no. 67/0984, corresponding to French patent no. 1,573,832 (Pratesi, Villa, Grana) 2. Farmaco Edizione Scientifica, vol.24 (3), pages 329-340 (1969) 3. Farmaco Edizione Scientifica, vol.22(8), pages 573-581 (1967) (Chemical Abstracts, vol. 67, 80849 - 1967) 4. French Patent No. 1,503 .517 (Bayer), equivalent to the U.S. Patent No. 3,334,188 (Wollweber) 5. Austrian Patent No. 252,215 (P.Somani, J. Med. Chem. 9, 823 - 1966)
Som spesielle tidligere kjente forbindelser, ifolge ovennevnte publikasjoner, kan fSigende nevnes: As particular previously known compounds, according to the above-mentioned publications, the following can be mentioned:
1-(4-metyltiofenyl)-2-isopropylaminoetanol-hydroklorid, 1-(4-methylthiophenyl)-2-isopropylaminoethanol hydrochloride,
(kalt forbindelse "A" heretter og kjent fra alle de ovennevnte publikasjoner), (called compound "A" hereinafter and known from all the above publications),
1-(4-metylsulfonylfenyl)-2-isopropylaminoetanol-hydroklorid, 1-(4-methylsulfonylphenyl)-2-isopropylaminoethanol hydrochloride,
(kalt forbindelse "B" heretter og kjent fra publikasjon nr. 5) , 1- (3,4-dimetyltiofényl)-2-isopropylaminoetanol-hydroklorid (kalt forbindelse "C" heretter og indirekte kjent fra publikasjon nr. 5) (called compound "B" hereafter and known from publication no. 5) , 1-(3,4-dimethylthiophenyl)-2-isopropylaminoethanol hydrochloride (called compound "C" hereafter and known indirectly from publication no. 5)
Nevnte kjente forbindelser har mindre interessante egenskaper Said known compounds have less interesting properties
i forhold-til de ovennevnte spesielt nevnte forbindelser ifSlge oppfinnelsen, hvilket vil bli vist i det etterfSigende. in relation to the above-mentioned especially mentioned compounds according to the invention, which will be shown in the following.
Oppfinnelsen omfatter også fremstillingen av ikke-toksiske salter av amino-alkoholer med formel 1, slik som hydroklorider, hydrobromider, fosfater, sulfater, oksalater, laktater, tartar-ater, acetater, sitrater og maleater. The invention also encompasses the production of non-toxic salts of amino alcohols with formula 1, such as hydrochlorides, hydrobromides, phosphates, sulphates, oxalates, lactates, tartrates, acetates, citrates and maleates.
Det er kjent at l-aryl-2-aminoetanol-derivatene har den egen-skapen å blokkere (3-adrenerg-reseptorene. It is known that the 1-aryl-2-aminoethanol derivatives have the property of blocking the (3-adrenergic receptors.
Det er funnet at selv om forbindelsene med den generelle formel I alltid har nevnte egenskap, vil de, selvom de er frie fra sympatikomimetiske virkninger, dessuten oppvise .andre farmakologiske aktiviteter, som skiller dem fra kjente produkter . It has been found that although the compounds of the general formula I always have the aforementioned properties, they will, even if they are free from sympathomimetic effects, also exhibit other pharmacological activities which distinguish them from known products.
Således vi produktene fremstilt ifolge nærværende oppfinnelse ha en markert periferisk vasodilatorisk virkning, som viser seg ved meget små doser. Thus, the products produced according to the present invention have a marked peripheral vasodilatory effect, which is evident at very small doses.
Det er også bemerket at nevnte produkter kan medfore en oksygensparing i hoyde med myokardium. It has also been noted that said products can lead to an oxygen saving in height with the myocardium.
På grunn av at de "blokkerende stoffer" for adrenerg-reseptorene ofte administreres når det er mangel på hjerte-oksygen (angina pectoris), er den til aktiviteten ledsagende okningen av hjertets virksomme ydeévne med nevnte P-lytiske virkning av åpenbar terapeutisk interésse. Due to the fact that the "blocking substances" for the adrenergic receptors are often administered when there is a lack of cardiac oxygen (angina pectoris), the accompanying increase in the heart's effective performance with the aforementioned β-lytic action is of obvious therapeutic interest.
Produktene fremstilt ifblge oppfinnelsen viser også en anti-arrytmisk og hypotensiv virkning. De nevnte produkters farmakologiske egenskaper gjor dem derfor anvendbare ved behandling og forebyggingav kransekar-lidelser, og ved behandling av hjerteforstyrrelser, som periferisk vasodilatator og som anti-hypertensor. The products produced according to the invention also show an anti-arrhythmic and hypotensive effect. The pharmacological properties of the mentioned products therefore make them useful in the treatment and prevention of coronary vessel disorders, and in the treatment of heart disorders, as a peripheral vasodilator and as an anti-hypertensive.
Deres blokkerende virkning av (3-adrenerg-reseptorene gir i forhold til kjente nærliggende forbindelser en metabolisk virkning av adrenergiske aminer og spesielt mobiliseres glu-kose og frie fettsyrer. Dessuten viser de nevnte forbindelser lav toksisitet, som tillater en langvarig og forsvarlig tera-pi. Their blocking effect of the (3-adrenergic receptors) compared to known nearby compounds gives a metabolic effect of adrenergic amines and glucose and free fatty acids in particular are mobilized. Moreover, the mentioned compounds show low toxicity, which allows a long-term and sound therapy .
Nevnte forbindelser fremstilles slik at de kan administreres oralt, rektalt eller parenteralt. Said compounds are prepared so that they can be administered orally, rectally or parenterally.
Således kan f.eks. forbindelsene for oral administrasjon være flytende eller faste. De kan fremstilles som tabletter, kapsler, granulater, pudder, siruper eller suspensjoner. Slike forbindelser inneholder additiver og eksipienser, som vanligvis anvendes i galenisk farmasi, inerte tilsetnings-stoffer, desintegrasjons-midler, bindemidler og mykgjorings-midler, som f.eks. laktose, stivelse, talkum, gelatin, stea-rinsyre, kiselsyre, magnesiumstearat, polyvinylpyrrolidon, kalsiumfosfat og kalsiumkarbonat. Thus, e.g. the compounds for oral administration be liquid or solid. They can be prepared as tablets, capsules, granules, powders, syrups or suspensions. Such compounds contain additives and excipients, which are usually used in galenic pharmacy, inert additives, disintegrants, binders and plasticizers, such as e.g. lactose, starch, talc, gelatin, stearic acid, silicic acid, magnesium stearate, polyvinylpyrrolidone, calcium phosphate and calcium carbonate.
De nye amino-alkoholer og salter av disse fremstilles ved at The new amino alcohols and their salts are produced by
a) en forbindelse med formel II a) a compound of formula II
reduseres, eller is reduced, or
b) en forbindelse med formel II, hvor Q er b) a compound of formula II, wherein Q is
hvor X betyr et halogenatom, where X means a halogen atom,
omsettes med et amin med formel NHR^Rg, is reacted with an amine of formula NHR^Rg,
og for fremstilling av forbindelser med den generelle formel I, hvor R^ betyr hydrogen and for the preparation of compounds of the general formula I, where R 1 means hydrogen
c) omsettes en forbindelse med formel II, hvor Q er CO-CO-R^ samtidig med et amin med formel NH2R5 eller c) a compound of formula II, where Q is CO-CO-R^ is reacted simultaneously with an amine of formula NH2R5 or
et hydroksylamin med formel MH(OH)R5 og et. reduksjonsmiddel , eller a hydroxylamine of formula MH(OH)R5 and et. reducing agent, or
d) en forbindelse med formel II, hvor Q er <:> omsettes under reduserende betingelser med en forbindelse med formel hvor R» og Rg har slike betydninger, at gruppen R^-CH-Rg får de for R^ foran angitte betydninger med unntak av hydrogen. e) redusere en forbindelse med formel II, hvori Q er d) a compound of formula II, where Q is <:> is reacted under reducing conditions with a compound of formula where R» and Rg have meanings such that the group R^-CH-Rg has the meanings given for R^ above with the exception of hydrogen. e) reducing a compound of formula II, wherein Q is
hvor Rg er en ved reduksjon avspaltbar gruppe. where Rg is a group cleavable by reduction.
Noen av de i krav 1 nevnte alternative fremgangsmåter er beskrevet i det folgende, og for letthets skyld er de defi-nert som fremgangsmåtene A til E. Some of the alternative methods mentioned in claim 1 are described in the following, and for the sake of simplicity they are defined as methods A to E.
Fremgangsmåte.. A Procedure.. A
Ifolge denne fremgangsmåte reduseres et oc-aminoketon med formel (II) , hvor Q betegner gruppen According to this method, an α-amino ketone of formula (II), where Q denotes the group, is reduced
hvor R, til Rg har den foran nevnte betydning. where R, to Rg have the aforementioned meaning.
Denne reduksjon kan utfores på vanlig måte, f.eks. ved . This reduction can be carried out in the usual way, e.g. by .
hydrering i nærvær av en katalysator, som f .eks. palladium på karbon, Raney-nikkel eller platina, i nærvær av et opplosningsmiddel som metanol eller etanol ved vanlig eller okt trykk. Reduksjonen kan også utfores med alkalimetallhydrider, hydration in the presence of a catalyst, such as palladium on carbon, Raney nickel or platinum, in the presence of a solvent such as methanol or ethanol at normal or octane pressure. The reduction can also be carried out with alkali metal hydrides,
som natriumborhydrid, og i en opplosning som metanol eller etanol, fortrinnsvis ved lavere temperatur, eller ved innvirkning av aluminium og litiumhydrid i eter eller tetrahydrofuran, fortrinnsvis ved lav temperatur, eller videre under innvirkning av aluminiumalkoksyd, som aluminiumisopropoksyd i en opplosning som isopropanol, og da helst ved tilbakelop av den sistnevnte. Det bor legges merke til at reduksjonen eventuelt kan utfores as sodium borohydride, and in a solution such as methanol or ethanol, preferably at a lower temperature, or by the action of aluminum and lithium hydride in ether or tetrahydrofuran, preferably at a low temperature, or further under the action of aluminum alkoxide, as aluminum isopropoxide in a solution such as isopropanol, and then preferably in the case of a relapse of the latter. It should be noted that the reduction can possibly be carried out
med et salt av forbindelse II (hydroklorid eller with a salt of compound II (hydrochloride or
oksalat) i tilfelle av en fremstilling av et amino-alkohol- oxalate) in the case of a preparation of an amino-alcohol-
salt. salt.
Utgangsforbindelser med den generelle formel II, hvor Q har Starting compounds of the general formula II, where Q has
den ovennevnte betydning, kan lett erholdes ved f.eks. inn- the above meaning, can be easily obtained by e.g. in-
virkning av et amin R^R^NH eller et a-halogenketon i inerte opplosningsmidler, som eter, benzen, kloroform, dioksan, en lavere alkohol som metanol, etanol eller isopropanol, eller også acetonitriler. Herved anvendes vanlig romtemperatur eller en lavere temperatur. Nevnte utgangsforbindelser kan også action of an amine R^R^NH or an α-halo ketone in inert solvents, such as ether, benzene, chloroform, dioxane, a lower alcohol such as methanol, ethanol or isopropanol, or also acetonitrile. Hereby, normal room temperature or a lower temperature is used. Said output connections can also
erholdes ved Houben-Hoesch-reaksjonen av et aminoalkylnitril is obtained by the Houben-Hoesch reaction of an aminoalkylnitrile
av typen CN-CH(R4) of the type CN-CH(R4)
og av passende substituerte benzen- and of suitably substituted benzene-
forbindelsér. H.D. Moed Ree. Trav.Chim. 71 933 (1952). connections. H. D. Courage Ree. Trot. Chim. 71,933 (1952).
Fremgangsmåte B Procedure B
Ifolge denne modifiserte fremgangsmåten reagerer en forbin-deise med formel (II), hvor Q betegner en av gruppene According to this modified method, a compound of formula (II) reacts, where Q denotes one of the groups
I med et amin av typen Rj-RgNH. I disse formler har til Rg ! og X deh samme betydning som tidligere nevnt. I with an amine of the type Rj-RgNH. In these formulas, to Rg ! and X deh the same meaning as previously mentioned.
1 1
i Denne spesielle modifiserte fremgangsmåten kan bedre vises ! ved hjelp av folgende réaksjonsskjerna: i This particular modified procedure can be better shown ! using the following reaction core:
Reduksjonen av forbindelsene med formel III kan utfores ifolge konvensjonelle fremgangsmåter som er beskrevet tidligere. The reduction of the compounds of formula III can be carried out according to conventional methods described previously.
Det er kjent fra litteraturen at man kan erholde enten forbindelse IV eller en blanding av forbindelsene IV og V, når reduksjonene utfores ved hjelp av metallhydrider. En av de nevnte forbindelser eller begge kan direkte reagere med et aminderivat R^R^NH. Det er likeledes vel kjent fra litteraturen at ved å la et amin innvirke på en forbindelse av typen IV for å oppnå forbindelse I, vil reaksjonen gå It is known from the literature that either compound IV or a mixture of compounds IV and V can be obtained when the reductions are carried out using metal hydrides. One of the aforementioned compounds or both can directly react with an amine derivative R^R^NH. It is likewise well known from the literature that by allowing an amine to act on a compound of type IV to obtain compound I, the reaction will proceed
via et intermediært epoksyd av typen V. Av praktiske grunner er det imidlertid.noen ganger lettere å danne epoksyd V kvantitativt ved behandling av produktet IV méd et basiskt middel, som natriumhydroksyd, kaliumhydroksyd eller et natrium-alkoksyd. via an intermediate epoxide of type V. For practical reasons, however, it is sometimes easier to form epoxide V quantitatively by treating the product IV with a basic agent, such as sodium hydroxide, potassium hydroxide or a sodium alkoxide.
Ved fremstilling av det forste epoksydet ble som opplosning smiddel anvendt f.eks. metanol, etanol, isopropanol, dioksan, benzen, dimetylformamid. Ved fremstillingen kan man i stedet for opplosningsmidler anvende et overskudd av amin-derivater. Reaksjonen foretaes ved en temperatur mellom romtemperatur og tilbakelopstemperaturen for det valgte opplosningsmidlet. Reaksjonen kan også med fordel utfores under trykk i en autoklav og et kondensasjons-middel, som natriumhydroksyd eller acetat, kan anvendes. In the production of the first epoxide, a solvent was used, e.g. methanol, ethanol, isopropanol, dioxane, benzene, dimethylformamide. During production, instead of solvents, an excess of amine derivatives can be used. The reaction is carried out at a temperature between room temperature and the reflux temperature for the chosen solvent. The reaction can also advantageously be carried out under pressure in an autoclave and a condensing agent, such as sodium hydroxide or acetate, can be used.
Forbindelser med formel I kan også erholdes ved å utgå fra forbindelse IV, og la denne reagere med et amin R^RgNH i et opplosningsmiddel, som dioksan, kloroform, etanol, isopropanol eller diglym. Det letteste er å utfore reaksjonen ved tilbakelopstemperaturen for det valgte opplosningsmidlet. Denne reaksjonen kan utfores i nærvær av et produkt som binder det frigjorte hydrogenhalogenidet, f.eks. en mineralbase eller et overskudd av det anvendte aminet. Compounds of formula I can also be obtained by starting from compound IV, and allowing this to react with an amine R^RgNH in a solvent, such as dioxane, chloroform, ethanol, isopropanol or diglyme. It is easiest to carry out the reaction at the reflux temperature of the chosen solvent. This reaction can be carried out in the presence of a product which binds the liberated hydrogen halide, e.g. a mineral base or an excess of the amine used.
Utgangsproduktene med formel III er lettest å erholde ved halogenering av de tilsvarende ketoner, eller også ved Friedel-Crafts-reaksjonen ved å utgå fra en passende substituert benzenforbindelse og fra syrehalogenider av typen X-CH(R^)-COX The starting products with formula III are easiest to obtain by halogenation of the corresponding ketones, or also by the Friedel-Crafts reaction starting from a suitably substituted benzene compound and from acid halides of the type X-CH(R^)-COX
(X halogen). (X halogen).
En epoksyd av typen V kan erholdes ved at et passende substituert benzaldehyd reagerer med et dimetylsulfoksonium eller dimetylsulfoniummetylid. An epoxide of type V can be obtained by reacting an appropriately substituted benzaldehyde with a dimethylsulfoxonium or dimethylsulfonium methylide.
I E.J. Corey J. Am. Chem. Soc. 87, 1353 (1965) In E.J. Corey J. Am. Chem. Soc. 87, 1353 (1965)
! A.Z. Britten Chem. & Ind. 771 41968). ! A.Z. Britten Chem. & Ind. 771 41968).
i in
i Fremgangsmåte C : " I Ifolge denne fremgangsmåten fremstilles de nye aminoalkohoiene j ved å omdanne én dikarbonylf orbindelse méd f ormél II, hvor Q I betegner gruppen Method C: According to this method, the new amino alcohols j are prepared by converting one dicarbonyl compound with formula II, where Q I denotes the group
i in
I og R har den tidligere nevnte betydning, I and R have the previously mentioned meaning,
: ved samtidig innvirkning av et amin R^RgNH eller av et hydroksyl-jamin RgR^NOH, hvor R^ til Rj. har den tidligere nevnte .betydning mens R^ betegner hydrogen og et reduksjonsmiddel. : by simultaneous action of an amine R^RgNH or of a hydroxylamine RgR^NOH, where R^ to Rj. has the previously mentioned meaning while R 1 denotes hydrogen and a reducing agent.
I Reduksjonen utfores ved katalytisk hydrering i nærvær åv :platina eller Raney-nikkel i f.eks. en "opplosning, som metanol feller etanol, ved enten atmosfærisk trykk eller ved forhoyet jtrykk. Reduksjonen kan også utfores ved hjelp av alkali-• metallhydrider, f.eks. natriumborhydrid, og i en losning av !metanol og fortrinnsvis ved lavere temperatur. I The reduction is carried out by catalytic hydrogenation in the presence of platinum or Raney nickel in e.g. a "solution, as methanol precipitates ethanol, at either atmospheric pressure or at elevated pressure. The reduction can also be carried out with the aid of alkali metal hydrides, e.g. sodium borohydride, and in a solution of !methanol and preferably at a lower temperature.
:Det bor legges merke til at reduksjonen kan utfores ved hjelp ,av bisulfit-derivater, hydrater eller acetalderivater av tidligere nevnt dikarbonylforbindelse. Nevnte forbindelse jenholdes enklest av tilsvarende acetofenon, når R^ = H, : It should be noted that the reduction can be carried out with the help of bisulphite derivatives, hydrates or acetal derivatives of the previously mentioned dicarbonyl compound. The mentioned compound is most easily represented by the corresponding acetophenone, when R^ = H,
jved innvirkning av et oksydasjonsmiddel, som selendioksyd under the influence of an oxidizing agent, such as selenium dioxide
i en opplosning av dioksan eller vann, eller ved innvirkning av dimetylsulf oksyd på en oc-halogenacetof enon av typen ifolge iformel III [N. Kornblum J. Am. Chem. Soc. Jl 6562 (1957)], ;eller også av oc-dihalogenacetofenoner [F. Venien CR. Acad. Sei. 266 1950 (1968)] eller ved hjelp av andre konvensjonelle fremgangsmåter som er vel kjente i litteraturen [Org. Synth. in a solution of dioxane or water, or by the action of dimethylsulfoxide on an oc-haloacetof enone of the type according to formula III [N. Kornblum J. Am. Chem. Soc. Jl 6562 (1957)], ;or also of oc-dihaloacetophenones [F. Venien CR. Acad. Pollock. 266 1950 (1968)] or by means of other conventional methods well known in the literature [Org. Synth.
II 511 et 48 109] . II 511 et 48 109] .
i in
Fremgangsmåte D Ifolge en annen modifikasjon av fremgangsmåten, erholdes de Method D According to another modification of the method, they are obtained
nye aminoalkohoiene ifolge oppfinnelsen ved å omsette en utgangsforbindelse med formel II, hvor Q betegner gruppen the new amino alcohols according to the invention by reacting a starting compound of formula II, where Q denotes the group
Y betegner enten et radikal - CO - eller Y denotes either a radical - CO - or
radikalet - CHOH- og R . har den tidligere nevnte betydning, under reduserende betingelser med en karbonylforbindelse av typen R"7RgC = 0, hvor R^ og Rg har slike betydninger at gruppen R7 - CH - Rg får de for R^ foranangitte betydninger med untak av hydrogen. the radical - CHOH- and R . has the previously mentioned meaning, under reducing conditions with a carbonyl compound of the type R"7RgC = 0, where R^ and Rg have such meanings that the group R7 - CH - Rg takes on the meanings given for R^ with the exception of hydrogen.
Den reduserende alkyleringen av en utgangsforbindelse av nevnte type utfores i nærvær av hydrogen og en hydrerings-katalysator, som platina, platinaoksyd eller palladium på The reductive alkylation of a starting compound of the aforementioned type is carried out in the presence of hydrogen and a hydrogenation catalyst, such as platinum, platinum oxide or palladium on
kull i et opplosningsmiddel, som metanol, etanol, etylacetat eller iseddik. Alkyleringen skjer ved vanlig trykk eller med fordel ved hoyere trykk, og videre med et alkalimetallhydrid som natrium-borhydrid i et opplosningsmiddel, som metanol, eller med aluminium og litiumhydrid i et opplosningsmiddel, som eter eller tetrahydrofuran. Man kan også arbeide uten opplosningsmiddel i nærvær av et overskudd av ketonforbind- " eisen. charcoal in a solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid. The alkylation takes place at normal pressure or advantageously at higher pressure, and further with an alkali metal hydride such as sodium borohydride in a solvent such as methanol, or with aluminum and lithium hydride in a solvent such as ether or tetrahydrofuran. One can also work without a solvent in the presence of an excess of the ketone compound ice.
Nevnte utgangsforbindelse kan dannes in situ av forbindelser ifolge formlene VI og VII: Said starting compound can be formed in situ from compounds according to formulas VI and VII:
! Y = CO A = CN, -N3, = N2, = NOH ! Y = CO A = CN, -N3, = N2, = NOH
!y = CHOH A = .N02, -CN, - N^ !y = CHOH A = .NO 2 , -CN, - N^
Ia-cyanofenylketoner (VI: Y = CO, A = CN) erholdes, f.eks. ved 'omsetning av et egnet substituert benz<p>ylklorid med et kupro-: cyanid [G. Zolss Sei. Pharm. 32 76 (1964)]; a-azido-og oc-diazo-!alkylketonene (VI: Y .= CO, A = N^ og = N2) fremstilles ifolge i i litteraturen velkj ente metoder (Houben-Weyl; Methoden der 'Organischen Chemie "Stickstoff Verbindingen I Vol 10/3); iisonitroketonene (VI: Y = CO, A = NOH) erholdes f.eks. av i egnede substituerte acetofenoner (R4 = H), propiofenoner (R^ = CH^) og lignende ved å la disse reagere med et alkylnitritt, som metyl, butyl eller amylnitritt i surt eller basiskt miljo; Ia-cyanophenyl ketones (VI: Y = CO, A = CN) are obtained, e.g. by 'reaction of a suitable substituted benzyl chloride with a cupro-: cyanide [G. Zols Sei. Pharm. 32 76 (1964)]; The a-azido- and o-diazo-!alkyl ketones (VI: Y .= CO, A = N^ and = N2) are prepared according to methods well known in the literature (Houben-Weyl; Methoden der 'Organischen Chemie "Stickstoff Verbindingen I Vol 10 /3); the isonitroketones (VI: Y = CO, A = NOH) are obtained, for example, from suitably substituted acetophenones (R4 = H), propiophenones (R^ = CH^) and the like by allowing these to react with an alkyl nitrite , such as methyl, butyl or amyl nitrite in acidic or basic environments;
|l-fenyl-2-nitroalkanoler (VK: Y = CHOH, A = - N02) erholdes Jf.eks. ved å omsette et egnet substituert benzaldehyd med et nitroalkan (nitrometan, nitroetan); cyanohydriner (VI; Y = CHOH; A = CN) erholdes av et egnet substituert benzaldehyd |l-phenyl-2-nitroalkanols (VK: Y = CHOH, A = - NO 2 ) are obtained E.g. by reacting a suitable substituted benzaldehyde with a nitroalkane (nitromethane, nitroethane); cyanohydrins (VI; Y = CHOH; A = CN) are obtained from a suitable substituted benzaldehyde
og en cyanohydrogensyre eller et salt av en slik med et alkali-metall; 1-fenyl-2-azidoalkanoler (VI: Y = CHOH, A = N3) erholdes f.eks. ved å omsette et epoksyd av typen V med hatriumazid [CA. Vanderwerf. J. Am. Chem. Soc 76 1231 (1954)]; and a cyanohydrogen acid or a salt thereof with an alkali metal; 1-phenyl-2-azidoalkanols (VI: Y = CHOH, A = N3) are obtained, e.g. by reacting a type V epoxide with sodium azide [CA. Vanderwerf. J. Am. Chem. Soc 76 1231 (1954)];
et oksazolidon av typen VII erholdes f.eks. av en forbindelse an oxazolidone of type VII is obtained, e.g. of a connection
av typen Ar - of type Ar -
av Curtius-omleiring. of Curtius rearrangement.
Den ovennevnte utgangsforbindelse kan også erholdes av et halogenketon av typen III under innvirkning av ftalimid, heksametylentetramin eller ammoniakk, eller også fra et epoksyd av typen V under innvirkning av ammoniakk. The above-mentioned starting compound can also be obtained from a halogen ketone of type III under the influence of phthalimide, hexamethylenetetramine or ammonia, or also from an epoxide of type V under the influence of ammonia.
Et halogenid av typen R'X kan også anvendes, hvor X betegner et halogen og R' et alkyl, substituert alkyl, cykloalkyl, alkenyl eller alkynylradikal. A halide of the type R'X can also be used, where X denotes a halogen and R' an alkyl, substituted alkyl, cycloalkyl, alkenyl or alkynyl radical.
Fremgangsmåte E Procedure E
Ifolge denne fremgangsmåten erholdes aminoalkoholer ifolge According to this method, amino alcohols are obtained as follows
oppfinnelsen ved å redusere en utgangsforbindelse med formel the invention by reducing a starting compound of formula
(II) hvor Q betegner - CHOH - CO - (II) where Q denotes - CHOH - CO -
gruppen, og R^the group, and R^
og Rg har den tidligere nevnte betydning. and Rg has the previously mentioned meaning.
Reduksjonen av en slik utgangsforbindelse foretaes enklest The reduction of such an output connection is done most simply
ved hjelp av et alkalimetallhydrid, som litiumaluminiumhydrid i en opplosning av dietyleter eller tetrahydrofuran, ved lavere temperaturer eller fortrinnsvis ved tilbakelopstemperaturen for det anvendte opplosningsmidlet. by means of an alkali metal hydride, such as lithium aluminum hydride in a solution of diethyl ether or tetrahydrofuran, at lower temperatures or preferably at the reflux temperature of the solvent used.
Salter av amino-alkoholer kan fremstilles ifolge oppfinnelsen, og som tidligere nevnt ved hjelp av den tidligere beskrevne generelle fremgangsmåten. Salts of amino alcohols can be prepared according to the invention, and as previously mentioned by means of the previously described general method.
Nevnte prosess omfatter flere varianter. Generelt kan de nevnte salter fremstilles ved hjelp av velkjente metoder ifolge den nevnte generelle fremgangsmåten, som f.eks. Said process includes several variants. In general, the aforementioned salts can be prepared using well-known methods according to the aforementioned general method, such as e.g.
ved reaksjon av ekvimolare mengder av amino-alkoholen med en syre i et egnet opplosningsmiddel som f.eks. en alkohol. Saltet utfelles ved å tilsette et annet opplosningsmiddel, by reaction of equimolar amounts of the amino alcohol with an acid in a suitable solvent such as e.g. an alcohol. The salt is precipitated by adding another solvent,
som er blandbart med det forstnevnte og i hvilket saltet er uloselig. Et slikt opplosningsmiddel er f.eks. eter. Utfellingen kan også foretaes ved nøytralisering med en which is miscible with the former and in which the salt is insoluble. Such a solvent is e.g. ether. The precipitation can also be carried out by neutralization with a
base eller syre av en eteropplosning av syren eller basen. Anvendte syrer er enten uorganiske syrer eller organiske syrer. Som uorganiske syrer anvendes fortrinnsvis saltsyre, bromhydrogensyre, svovelsyre, fosforsyre og perklbr-.syre. Av organiske syrer anvendes karboksylsyrer, eller sulfonsyrer, som maursyre, eddiksyre, propionsyre, glykolsyre, base or acid of an ether solution of the acid or base. Acids used are either inorganic acids or organic acids. As inorganic acids, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid and perchloric acid are preferably used. Of the organic acids used are carboxylic acids, or sulphonic acids, such as formic acid, acetic acid, propionic acid, glycolic acid,
melkesyre, sitronsyre-, askorbinsyre-, fumarsyre, maleiirsyrer, pamoinsyre,, ravsyre^ vinsyrer,, fenyleddrksyre, benzosyre:, p-aminobenzosyre, antranilsyre, p-hydroksybenzosy^e.^: salicyl-syre, metransulf onsyre og. etandisulf onsyrev lactic acid, citric acid, ascorbic acid, fumaric acid, maleic acid, pamoic acid, succinic acid, tartaric acid, phenylacetic acid, benzoic acid:, p-aminobenzoic acid, anthranilic acid, p-hydroxybenzosy^e.^: salicylic acid, metransulfonic acid and. ethanedisulfonic acid rev
En annen variant av den generelle: fremgangsmåten" for: fremstilling av salter, hvor Q- i. formel II betegner en: av gruppene Another variant of the general: method" for: preparation of salts, where Q- i. formula II denotes one: of the groups
grupper, Y og R4 til groups, Y and R4 to
Rg har den tidligere angitte betydning, består i en direkte reduksjon til et salt av utgangsforbindelsen. Således erholdes et salt som tilsvarer en amino-alkqhol med formel (I). Rg has the previously indicated meaning, consists in a direct reduction to a salt of the starting compound. Thus a salt corresponding to an amino alcohol of formula (I) is obtained.
Hver enkelt av de nevnte varianter av fremgangsmåten ifolge oppfinnelsen illustreres i det folgende ved hjelp av relativt detaljerte fremstillings-eksempler av en serie forbindelser. De nevnte eksemplene ledsages av en tabell som viser egen-skapene til en viktig gruppe forbindelser, som ble fremstilt ifolge de nevnte modifikasjonene av fremgangsmåten ved fremstillingen. Each of the aforementioned variants of the method according to the invention is illustrated in the following by means of relatively detailed production examples of a series of compounds. The mentioned examples are accompanied by a table showing the properties of an important group of compounds, which were prepared according to the mentioned modifications of the method of preparation.
Eksempel 1 Example 1
1- ( 3- metvl- 4- metyltiofenvl)- 2- t- butvlaminobutanol 1-(3-methyl-4-methylthiophenyl)-2-t-butylaminobutanol
a) 160 g aluminiumklorid i 650 ml kloroform tilsettes ved en temperatur på 0 - 5°C 125 g butyrylklorid og deretter a) 160 g aluminum chloride in 650 ml chloroform is added at a temperature of 0 - 5°C 125 g butyryl chloride and then
langsomt 138 g l-metyl-2-metyltiobenzen. Blandingen omrores 2 timer ved romtemperatur, og deretter helles blandingen til is og saltsyre. Blandingen ekstraheres med. eter og torkes over magnesiumsulfat. Etter å ha avdampet opplosningsmidlet slowly 138 g of 1-methyl-2-methylthiobenzene. The mixture is stirred for 2 hours at room temperature, and then the mixture is poured into ice and hydrochloric acid. The mixture is extracted with ether and dried over magnesium sulfate. After evaporating the solvent
destilleres inndampningsresten i vakuum. Man erholder 166 g 3-metyl-4^metyltidbutyrofenon. Kokepunkt (k.p.) =132 137°C the evaporation residue is distilled in vacuum. 166 g of 3-methyl-4-methyltidebutyrophenone are obtained. Boiling point (b.p.) =132 137°C
(0,1 mm); smeltepunkt (s.p.: 45 - 46°C; utbytte 80%. (0.1mm); melting point (m.p.: 45 - 46°C; yield 80%
b) 165 g 3-métyl-4-metyltiobutyrofenon i 500 ml eteranhydrid tilsettes sakte under omroring 128 g brom. Temperaturen b) 165 g of 3-methyl-4-methylthiobutyrophenone in 500 ml of ethereal anhydride is slowly added while stirring with 128 g of bromine. The temperature
holdes ved 10°C. Efter tilsetningen får blandingen innta romtemperatur, og den behandles med en 10%'ig vandig NaHCO^-losning inntil en misfargning av den organiske fasen viser seg. Den organiske fasen torkes over magnesiumsulfat og opplosningsmidlet avdampes i vakuum. Man erholder 160 g 3-metyl-4-metyltio-a-brombutyrofenon. S.p. (°C): 86,5 - 88,5; utbytte: 71%. kept at 10°C. After the addition, the mixture is allowed to reach room temperature, and it is treated with a 10% aqueous NaHCO 3 solution until a discoloration of the organic phase appears. The organic phase is dried over magnesium sulphate and the solvent is evaporated in vacuo. 160 g of 3-methyl-4-methylthio-a-bromobutyrophenone is obtained. S. p. (°C): 86.5 - 88.5; yield: 71%.
c) 8,64 g 3-metyl-4-metyltio-a-brombutyrofenon i 100 ml acetonitrilanhydrid tilsettes 8,76 g t-butylamin, og blandingen c) 8.64 g of 3-methyl-4-methylthio-a-bromobutyrophenone in 100 ml of acetonitrile anhydride is added to 8.76 g of t-butylamine, and the mixture
omrores 24 timer ved romtemperatur. Derefter tilsettes 200 stirred for 24 hours at room temperature. Then add 200
ml eter og t-butylaminhydrobromidet avfiltreres og vaskes med eter. ml of ether and the t-butylamine hydrobromide is filtered off and washed with ether.
Den organiske fasen vaskes med vann, torkes over magnesium- The organic phase is washed with water, dried over magnesium
sulf at og inndampes i vakuum. Den resterende rode oljen, sulfate and evaporated in vacuo. The remaining red oil,
hvis homogenitet proves ved tynnfilms-kromatografi, anvendes som sådan ved de efterfSigende arbeidsoperasjoner. whose homogeneity is proven by thin-film chromatography, is used as such in the subsequent work operations.
d) Til det erholdte produkt fra den forangående arbeids- d) To the product obtained from the previous work
operasjon og 100 ml metanol tilsettes langsomt 2,3 g natrium-borhydrid under omroring. Temperaturen holdes ved 10°C. operation and 100 ml of methanol, slowly add 2.3 g of sodium borohydride while stirring. The temperature is kept at 10°C.
Omroringen fortsetter ytterligere 2 timer ved romtemperatur, , og derefter avdampes opplosningsmidlet i vakuum. Residumet taes opp med vann og ekstraheres med eter. Den organiske fasen tSrkes over magnesiumsulfat, og hydroklorid erholdes ved en gjennomstrSmning av torr HCl-gass. 4,9 g av produktet erholdes. Totalt utbytte ved arbeidsoperasjonene c og d: 51%. Stirring continues for a further 2 hours at room temperature, and then the solvent is evaporated in vacuo. The residue is taken up with water and extracted with ether. The organic phase is solidified over magnesium sulfate, and the hydrochloride is obtained by passing through dry HCl gas. 4.9 g of the product is obtained. Total yield for work operations c and d: 51%.
En analytisk prove rekrystalliseres flere ganger i metanol-eter-blånding. S.p. (°C): 235 - 237°. An analytical sample is recrystallized several times in a methanol-ether mixture. S. p. (°C): 235 - 237°.
I Analyser ' Beregnet (%): C: 66,45 H: 8,88 N: 4,41 I Analyzes ' Calculated (%): C: 66.45 H: 8.88 N: 4.41
Funnet (%): C: 60,25 H-s": 8,80 N:.4,21 Found (%): C: 60.25 H-s": 8.80 N:.4.21
i in
j Eksempel 2 j Example 2
j 1- ( 3- metvl- 4- metvltiofenvi)- 2^ N- ( 4- benzylpiperidino) efeanol j 1-( 3- methyl- 4- methylthiopheni)- 2^ N-( 4- benzylpiperidino) ephanol
I a) 116 g aliiminiumklorid i 600 ml kloroform tilsettes- 65 g ace-j tylklorid. Derefter tilsettes;; langsomt ved en temperatur på In a) 116 g of aluminum chloride in 600 ml of chloroform are added - 65 g of acetyl chloride. Then add;; slowly at a temperature of
jo - 5°c, 105 g l-metyl-2-metyltiobenzen. Blandingen-omrbres '2,5 timer ved romtemperatur, bg derefter helles den til is ! og saltsyre. Den ekstraheres med eter og torkes over magnesium-i , ■ - jo - 5°c, 105 g of 1-methyl-2-methylthiobenzene. The mixture is stirred for 2.5 hours at room temperature, then poured into ice. and hydrochloric acid. It is extracted with ether and dried over magnesium-i , ■ -
j sulfat. Efter avdampning av opplosningsmidlet destilleres ! inndampnings-resten i vakuum. Man erholder 109 g 3-metyl-4-jmetyltioacetofenon. Kp.: 125° (1 mm)5 n^ (refraksjonsindeks) 1,61205 utbytte: 80%. j sulfate. After evaporation of the solvent, distill ! the evaporation residue in vacuum. 109 g of 3-methyl-4-methylthioacetophenone are obtained. Kp.: 125° (1 mm)5 n^ (refractive index) 1.61205 yield: 80%.
ib) 600 g 3-métyl-4-metyltibacetofenon (3.3 M) i 2000 ml ! vannfri eter tilsettes dråpevis 169 mi brom (3.3 M). Efter \tilsetningen fortsettes omrbringen 1,5 timer ved romtemperatur. Derefter behandler man blandingen med 500 ml 10%'ig ibikarbonatopplbsning. Den organiske fasen avskilles, torkes !over magnesiumsulfat og avdampes inntil 1/3 av det opprinnelige 'volumet gjenstår. Det tilsettes 300 ml petroleumetér og det 1 erholdte bunnfallet filtreres. Man erholder 790 g 3-metyl-4-[ metyltio-oc-bromacetof enon. S.p. (°C) : 66 - 68°; utbytte: 92%. ib) 600 g 3-methyl-4-methyltibacetophenone (3.3 M) in 2000 ml ! 169 ml of bromine (3.3 M) are added dropwise to anhydrous ether. After the addition, stirring is continued for 1.5 hours at room temperature. The mixture is then treated with 500 ml of 10% bicarbonate solution. The organic phase is separated, dried over magnesium sulphate and evaporated until 1/3 of the original volume remains. 300 ml of petroleum ether are added and the precipitate obtained is filtered. 790 g of 3-methyl-4-[methylthio-oc-bromoacetof enone are obtained. S. p. (°C) : 66 - 68°; yield: 92%.
jc). 13,5 g 3-metyl-4-metyltio-a-bromoacetofenon (0,05 M) i jc). 13.5 g of 3-methyl-4-methylthio-α-bromoacetophenone (0.05 M) in
100 ml vannfri eter tilsettes 17,5 g 4-benzylpiperidin (0,1 M). • Dette omrbres over natten ved romtemperatur. Hydrobromidet filtreres fra utgangsaminet og opplosningsmidlet avdampes i vakuum. Det erholdte produktet anvendes direkte ved den 'efterfolgende arbeidsoperasjon. 100 ml of anhydrous ether is added to 17.5 g of 4-benzylpiperidine (0.1 M). • This is stirred overnight at room temperature. The hydrobromide is filtered from the starting amine and the solvent is evaporated in vacuo. The product obtained is used directly in the subsequent work operation.
d) 16 g 3-metyl-4-metyltio-a-N-(4-benzylpiperidino)acetofenon 'i 75 ml metanol og 6 ml 0,02 N natriumhydroksyd tilsettes langsomt under kjbling ved hjelp av isbad 1,5 g natriumborhydrid. Blandingen omrbres 90 minutter ved romtemperatur, derefter surgjores den med 2-N HC1 og fortynnes med det samme volum vann. Derefter vaskes den vandige f-asen med eter. -Man gjor alkalisk med 20%'ig NaOH og ekstraherer med eter. Den organiske fasen torkes over magnesiumsulf at og hydr oklor idet: erholdes ved gjennomstrømning av torr HCl-gass. Man erholder 14 g av produktet (utbytte: 87%). En prove rekrystalliseres for analyse i metanol-eter-blanding. S.p. (°C): 234 - 235. d) 16 g of 3-methyl-4-methylthio-a-N-(4-benzylpiperidino)acetophenone in 75 ml of methanol and 6 ml of 0.02 N sodium hydroxide are added slowly while stirring using an ice bath 1.5 g of sodium borohydride. The mixture is stirred for 90 minutes at room temperature, then acidified with 2-N HCl and diluted with the same volume of water. The aqueous phase is then washed with ether. - Make alkaline with 20% NaOH and extract with ether. The organic phase is dried over magnesium sulfate and hydrogen chloride, which is obtained by flowing through dry HCl gas. 14 g of the product is obtained (yield: 87%). A sample is recrystallized for analysis in a methanol-ether mixture. S. p. (°C): 234 - 235.
Analyser Analyze
% beregnet: C: 67,40 H: 7,71 N: 3,57 % calculated: C: 67.40 H: 7.71 N: 3.57
% funnet: C: 67,47 H: 7,55 N: 3,55 % found: C: 67.47 H: 7.55 N: 3.55
Eksempel 3 Example 3
1- ( 3- karbometoksv- 4- metyltiofenyl)- 2- N- piperidinoetanol 1- ( 3- carbomethoxy- 4- methylthiophenyl)- 2- N- piperidinoethanol
a) 3- karbometoksv- 4- metyltioacetofenon a) 3- carbomethoxy- 4- methylthioacetophenone
Produktet erholdes ved Friedel-Crafts-reaksjonen av 1-karbometoksy-2-metyltiobenzen (CH^COCl, CS, AlCl^; under tilbakelop 4 timer på vann-bad). The product is obtained by the Friedel-Crafts reaction of 1-carbomethoxy-2-methylthiobenzene (CH^COCl, CS, AlCl^; under reflux for 4 hours on a water bath).
Utbytte: 43%; s.p. (°C): 99 - 102 {isopropanol). Yield: 43%; s.p. (°C): 99 - 102 (isopropanol).
b) 3- karbometoksy- 4- metyltio- a- bromacetofenon Erholdt ved bromering av det foregående produktet med brom b) 3- carbomethoxy- 4- methylthio- a- bromoacetophenone Obtained by bromination of the preceding product with bromine
(opplosningsmiddel: eter-dioksan 2/1, romtemperatur). (solvent: ether-dioxane 2/1, room temperature).
Utbytte: 73%, s.p. (°C): 145 - 146 (benzen-etyl-acetat). Yield: 73%, s.p. (°C): 145 - 146 (benzene-ethyl acetate).
Analyser Analyze
% beregnet: C: 43,58 H: 3,66 % calculated: C: 43.58 H: 3.66
% funnet: C: 43,71 H: 3,85 % found: C: 43.71 H: 3.85
c) 3- karbometoksv- 4- metvltio- oc- N- piperidino- acetof enon Erholdt ved omsetning av piperidin med det foran—nevnte produkt c) 3-carbomethoxy-4-methylthio-oc-N-piperidino-acetofenone Obtained by reacting piperidine with the above-mentioned product
(opplosningsmiddel: acetonitril, 24 timer ved romtemperatur). Produktet er ikke rengjort; dets homogenitet proves ved tynnsjiktskromatograf i. d) 1-( 3- karbometoksy- 4- metyltiofenyl)- 2- N- piperidinoetanol Erholdt ved reduksjon av det foran-nevnte produkt med natrium-borhydrid (opplosningsmiddel: metanol, temperatur: 10°C. Utbytte: 63%; s.p. (°C): 199,5 - 201,5 (metanol-eter). (solvent: acetonitrile, 24 hours at room temperature). The product is not cleaned; its homogeneity is proven by thin-layer chromatography i. d) 1-(3-carbomethoxy-4-methylthiophenyl)-2-N- piperidinoethanol Obtained by reduction of the above-mentioned product with sodium borohydride (solvent: methanol, temperature: 10°C. Yield: 63%, mp (°C): 199.5 - 201.5 (methanol-ether).
I Fremstilling av det tilsvarende hydrokloridet ifolge tidligere eksempler. I Preparation of the corresponding hydrochloride according to previous examples.
! Analyser ! Analyze
beregnet: C: 55,56 H: 6,99 N: 4,05 calcd: C: 55.56 H: 6.99 N: 4.05
J % funnet: C: 55,40 H: 6,90 N: 3,90' J % found: C: 55.40 H: 6.90 N: 3.90'
i in
, Eksempel 4 , Example 4
' 1-( 4- n- butyltio- 3- metvlfenyl)- 2- piperidinoetanol i a) Til en godt omrort blanding av 283 aluminiumklorid i 1150 'ml vannfri kloroform tilsettes langsomt ved en temperatur pa 0 - 10°C 180 g acetylklorid og derefter 520 g 4-n-butyltio-3-metylbenzen. Blandingen får innta romtemperatur og ;hydrolyseres derefter ved tilsetning av is og saltsyre. Efter vanlig behandling erholdes 324 g 4-n-butyltio-3-métylaceto-. i fenon. iK.p.: 164 - 166° (2 mm)5 n£<5> = 1,5763; utbytte: 82%.. 1-(4-n-butylthio-3-methylphenyl)-2-piperidinoethanol in a) To a well-stirred mixture of 283 aluminum chloride in 1150 ml of anhydrous chloroform, add slowly at a temperature of 0 - 10°C 180 g of acetyl chloride and then 520 g of 4-n-butylthio-3-methylbenzene. The mixture is allowed to reach room temperature and is then hydrolysed by adding ice and hydrochloric acid. After the usual treatment, 324 g of 4-n-butylthio-3-methylaceto- are obtained. in phenone. iK.p.: 164 - 166° (2 mm)5 n£<5> = 1.5763; yield: 82%..
1b) Ved bromering av foregående produkt med brom i vannfri eter, erholdes 4-n butyltio-3-metyl-a-bromacetofenon. 1b) By bromination of the preceding product with bromine in anhydrous ether, 4-n-butylthio-3-methyl-a-bromoacetophenone is obtained.
S.p. (°C): 59,5 - 60,5 (isopropanol). S. p. (°C): 59.5 - 60.5 (isopropanol).
c) Det erholdte produkt fra foregående arbeidsoperasjon ,behandles med to ekvivalente mengder piperidin (opplosnings-imiddel: vannfri eter; 18 timer ved romtemperatur). Piperidinhydrobromid avfiltreres og vaskes med eter. Efter ;avdampning av opplosningsmidlet proves homogeniteten av det erholdte oc-piperidino-4-n-butyltio-3-metylacetofenon ved hjelp av tynnsjiktskromatografering, og det nevnte produktet anvendes som sådant ved den efterfolgende arbeidsoperasjon. d) Reduksjonen av det foregående produkt med natriumborhydrid 1 metanol ved 0°C gir 1-(4-n-butyltio-3-metylfenyl)-2-piperidinoetanol . c) The product obtained from the preceding work operation is treated with two equivalent amounts of piperidine (solvent: anhydrous ether; 18 hours at room temperature). Piperidine hydrobromide is filtered off and washed with ether. After evaporation of the solvent, the homogeneity of the obtained oc-piperidino-4-n-butylthio-3-methylacetophenone is tested by means of thin-layer chromatography, and the aforementioned product is used as such in the subsequent work operation. d) The reduction of the preceding product with sodium borohydride 1 methanol at 0°C gives 1-(4-n-butylthio-3-methylphenyl)-2-piperidinoethanol.
S.p. (°C): 157 - 159 (MeOH-eter). S. p. (°C): 157 - 159 (MeOH-ether).
Analyser Analyze
% beregnet: C: 62,86 H: 8,79 N: 4,07 % calcd: C: 62.86 H: 8.79 N: 4.07
% funnet: C: 62,98 H: 8,77 N: 3,90 % found: C: 62.98 H: 8.77 N: 3.90
Eksempel 5 Example 5
1- ( 3- metvl- 4- metyltiofenyl)- 2- isopropylaminoetanol 11,8 g a-isopropylamino-3-metyl-4-metyltioacetofenon (0,05 mol) 1-(3-methyl-4-methylthiophenyl)-2-isopropylaminoethanol 11.8 g α-isopropylamino-3-methyl-4-methylthioacetophenone (0.05 mol)
i 100 ml metanol tilsettes ved å holde temperaturen på 0 - 10° 3,8 g NaBH^ (0,2 mol). Omroringen fortsetter en time ved denne temperatur, og derefter avdampes opplosningsmidlet i vakuum. Blandingen behandles med vann, og derefter eks- in 100 ml of methanol, 3.8 g of NaBH^ (0.2 mol) are added by keeping the temperature at 0 - 10°. Stirring continues for one hour at this temperature, and then the solvent is evaporated in vacuo. The mixture is treated with water, and then ex-
traheres den med eter. Den organiske fasen torkes over magnesiumsulfat og avdampes. 9,6 g (utbytte på 81,3%) av den frie basen erholdes, og denne kan rekrystalliseres i en blanding av eter-petroleter. S.p: 89,5 - 90,5°. l-(3-metyl-4-metyltiofenyl)-2-isopropylaminoetanol-hydroklorid erholdes ved gjennomstrømning av torr HCl-gass i en eterholdig losning av den frie basen og ved rekrystallisering i metanol-eter-blanding. S.p.: 154,5 - 155,5°C. it is extracted with ether. The organic phase is dried over magnesium sulfate and evaporated. 9.6 g (yield of 81.3%) of the free base is obtained, and this can be recrystallized in a mixture of ether-petroleum ether. M.p.: 89.5 - 90.5°. 1-(3-methyl-4-methylthiophenyl)-2-isopropylaminoethanol hydrochloride is obtained by flowing through dry HCl gas in an ethereal solution of the free base and by recrystallization in a methanol-ether mixture. M.p.: 154.5 - 155.5°C.
Analyser Analyze
% beregnet: C: 56,58 H: 8,04 N: 5,08 % calcd: C: 56.58 H: 8.04 N: 5.08
% funnet: C: 56,52 H: 8,04 N: 5,28 % found: C: 56.52 H: 8.04 N: 5.28
Eksempel 6 Example 6
1-( 4- n- butyltio- 3- metylfenyl)- 2- cvkloheksylaminoetanol 5,7 g (0,0158 mol) a-cykloheksylamino-4-n-butyltio-3-metyl-acetofenon-hydroklorid i 50 cc metanol tilsettes langsomt ved en temperatur på 0 - 10° 1,2 g NaBH^. Omroringen fortsetter to timer ved romtemperatur, og derefter avdampes opplosningsmidlet i vakuum. Det tilsettes vann og ekstra- 1-(4-n-butylthio-3-methylphenyl)-2-cyclohexylaminoethanol 5.7 g (0.0158 mol) α-cyclohexylamino-4-n-butylthio-3-methyl-acetophenone hydrochloride in 50 cc of methanol are added slowly at a temperature of 0 - 10° 1.2 g NaBH^. Stirring is continued for two hours at room temperature, and then the solvent is evaporated in vacuo. Water is added and additional
heres med eter. Eterfasen torkes over magnesiumsulfat og efter filtrering og gjennomstromning av torr HCl-gass. erholdes 4,2 g 1-(4-n-butyltio-3-metylfenyl)-2-cykloheksylaminoetanol HC1. Dette rekrystalliseres i etylacetat. S.p.: 135,5 - 136,5°C. here with ether. The ether phase is dried over magnesium sulphate and after filtration and a flow of dry HCl gas. 4.2 g of 1-(4-n-butylthio-3-methylphenyl)-2-cyclohexylaminoethanol HC1 are obtained. This is recrystallized in ethyl acetate. M.p.: 135.5 - 136.5°C.
Analyser Analyze
% beregnet: C: 63,75 H: 9,01 N: 3,91 % calcd: C: 63.75 H: 9.01 N: 3.91
% funnet: C: 63,78 H: 8,90 N: 8,83 % found: C: 63.78 H: 8.90 N: 8.83
Eksempel 7 Example 7
I 1-( 3- metvl- 4- metvltiofenvl)- 2- N. N- dipropylaminoetanol I 1-(3-methyl-4-methylthiophenyl)-2-N.N-dipropylaminoethanol
j a) 55 g 3-metyl-4-metyltio-a-bromacetofenon i 200 ml iso-j propanol og 125 g aluminiumisopropoksyd i 300 ml isopropanol j a) 55 g 3-methyl-4-methylthio-a-bromoacetophenone in 200 ml iso-j propanol and 125 g aluminum isopropoxide in 300 ml isopropanol
.-j kokes under tilbåkelop "hver for seg. .-j are boiled under a gentle heat "each separately.
i in
i in
i Begge lbsningene blandes og kokes under tilbåkelop 15 minutter. I Derefter avkjbler man og surgjor med 50% saltsyre i nærvær av is. Det erholdte presipitatet filtreres og vaskes med vann. jEfter tbrking erholdes 50,8 g 1-(3-metyl-4-metyltiofenyl)-2-ibrometanol. S.p. (°C): 74 - 76; utbytte 92%. Produktet <!>kan rekrystalliseres i cykloheksan. S.p. ( C): 78 - 79. Both mixtures are mixed and boiled for 15 minutes. Then cool down and acidify with 50% hydrochloric acid in the presence of ice. The precipitate obtained is filtered and washed with water. After distillation, 50.8 g of 1-(3-methyl-4-methylthiophenyl)-2-ibromethanol are obtained. S. p. (°C): 74 - 76; yield 92%. The product <!> can be recrystallized in cyclohexane. S. p. (C): 78-79.
1 Analyser 1 Analyze
1% beregnet: C: 45,99 H: 5,02 1% calculated: C: 45.99 H: 5.02
\% funnet: C: 45,95 H: 5,05 \% found: C: 45.95 H: 5.05
i in
<j>b) 13 g 1-(3-metyl-4-metyltiofenyl)-2-brometanol i 50 ml etanol i tilsettes en opplosning av 4,2 g KOH i 25 ml etanol. Blan-;dingen omrores 30 minutter ved romtemperatur, og derefter Iavfiltreres det dannede saltet. b) 13 g of 1-(3-methyl-4-methylthiophenyl)-2-bromoethanol in 50 ml of ethanol is added to a solution of 4.2 g of KOH in 25 ml of ethanol. The mixture is stirred for 30 minutes at room temperature, and then the formed salt is filtered off.
jUtspedning foretaes med det samme volum vann, og ekstraksjon I foretaes med eter. Den organiske fasen torkes over magnesium-I sulfat og inndampes. Den oljelignende inndampningsresten jDilution is carried out with the same volume of water, and extraction I is carried out with ether. The organic phase is dried over magnesium sulfate and evaporated. The oil-like evaporation residue
i in
..anvendes som sådan ved den efterfolgende arbeidsoperasjon. ..is used as such in the following work operation.
:c) 6,5 g 3-metyl-4-metyltiofenyletylenoksyd i 50 ml etanol tilsettes 15 g di-n-propylamin, og dette kokes under tilbåkelop natten over. Opplosningsmidlet og overskudd av amin avdampes i vakuum. Den" oljelignende inndampnings-resten taes opp med eter og behandles med torr HCl-gass. •Den erholdte oljen behandles med aceton, derefter med etyl-acetat. Det erholdte produktet rekrystalliseres i isopropanol. :c) 6.5 g of 3-methyl-4-methylthiophenylethylene oxide in 50 ml of ethanol is added to 15 g of di-n-propylamine, and this is boiled overnight. The solvent and excess amine are evaporated in vacuo. The oil-like evaporation residue is taken up with ether and treated with dry HCl gas. • The oil obtained is treated with acetone, then with ethyl acetate. The product obtained is recrystallized in isopropanol.
S.p,' (°C) : 161 - 162. S.p.' (°C) : 161 - 162.
Analyser Analyze
% beregnet: C: 60,44 H: 8,88 N: 4,41 % calcd: C: 60.44 H: 8.88 N: 4.41
% -funnet: C: 60,30 H: 8,85 N: 4,28 % found: C: 60.30 H: 8.85 N: 4.28
Eksempel 8 Example 8
1-( 3- metyl- 4- metyltiofenyl)- 2- ( ococ- dimetvlfenvletylamino) etanol 1-( 3- methyl- 4- methylthiophenyl)- 2-( ococ- dimethylphenvletylamino) ethanol
a) 20 g 1-(3-metyl-4-metyltiofenyl)-2-brometanol i 100 ml metanol behandles med 1,5 ekvivalente deler av NaOH i 30 ml a) 20 g of 1-(3-methyl-4-methylthiophenyl)-2-bromoethanol in 100 ml methanol is treated with 1.5 equivalent parts of NaOH in 30 ml
metanol. Blandingen omrbres 30 minutter ved romtemperatur og fortynnes derefter med vann. Produktet ekstraheres med eter, torkes over magnesiumsulfat og opplosningsmidlet avdampes i vakuum. Det erholdte epoksydet, hvis homogenitet proves ved hjelp av tynnsjiktskromatografering, anvendes som sådan ved den efterfolgende arbeidsoperasjon. methanol. The mixture is stirred for 30 minutes at room temperature and then diluted with water. The product is extracted with ether, dried over magnesium sulfate and the solvent is evaporated in vacuo. The epoxide obtained, whose homogeneity is proven by means of thin-layer chromatography, is used as such in the subsequent work operation.
b) Den erholdte oljen fra den foregående arbeidsoperasjonen, 50 ml metanol og 20 g a,oc-dimetylfenyletylamin kokes 48 timer b) The oil obtained from the preceding work operation, 50 ml of methanol and 20 g of a,oc-dimethylphenylethylamine are boiled for 48 hours
under tilbåkelop. Opplosningsmidlet og overskudd av amin avdampes i vakuum. Den oljelignende inndampningsresten taes opp med eter og ekstraheres med 20%'ig HC1. Den vandige fasen gjores basisk med 50%'ig NaOH og ekstraheres med eter. Eterfasen torkes over magnesiumsulfat og avdampes. Den oljelignende inndampnings-resten krystalliserer i kjoleskap. Dette behandles med diisopropyleter og 5 g produkt isoleres. S.p. (°C): 99 - 100; hydroklorid: s.p. (°C): 144 - 145,5. during return run. The solvent and excess amine are evaporated in vacuo. The oil-like evaporation residue is taken up with ether and extracted with 20% HCl. The aqueous phase is made basic with 50% NaOH and extracted with ether. The ether phase is dried over magnesium sulfate and evaporated. The oil-like evaporation residue crystallizes in a refrigerator. This is treated with diisopropyl ether and 5 g of product is isolated. S. p. (°C): 99 - 100; hydrochloride: m.p. (°C): 144 - 145.5.
Analyser (fri base) Analyze (free base)
% beregnet: C: 72,90 H: 8,26 N: 4,25 % calculated: C: 72.90 H: 8.26 N: 4.25
% funnet: C: 72,70 H: 8,30 N: 4,05 % found: C: 72.70 H: 8.30 N: 4.05
Eksempel 9 Example 9
1-( 4- etyltio- 3- metylfenyl)- 2- cyklopentylaminoetanolhydroklorid a) 4-etyltio-3-metylacetofenon fremstilles ved å omsette acetylklorid og aluminiumklorid i kloroform med l-etyltio-2-metylbenzen ifolge allerede beskrevne fremgangsmåter. 1-(4-ethylthio-3-methylphenyl)-2-cyclopentylaminoethanol hydrochloride a) 4-ethylthio-3-methylacetophenone is prepared by reacting acetyl chloride and aluminum chloride in chloroform with l-ethylthio-2-methylbenzene according to methods already described.
K.p.: 117 - 119°C (0,25 mm). b) 4-etyltio-3-metyl-a-bromacetofenon erholdes ved bromering av det foregående produkt med brom i vannfri eter. B.p.: 117 - 119°C (0.25 mm). b) 4-ethylthio-3-methyl-a-bromoacetophenone is obtained by bromination of the preceding product with bromine in anhydrous ether.
I S.p. (°C): 72 - 73°. In S. p. (°C): 72 - 73°.
] c) 1-(4-etyltio-3-metylfenyl)-2-brometanol erholdes ved I reduksjon av det foregående produkt med aluminiumisopropoksyd ] c) 1-(4-ethylthio-3-methylphenyl)-2-bromoethanol is obtained by reduction of the preceding product with aluminum isopropoxide
' ', i isopropanol. S.p. ( oC) : 74 - 75. ' ', in isopropanol. S. p. (oC) : 74 - 75.
i in
! d) 5,5 g (0,02 M) 1-(4-etyltio-3-metylfenyl)-2-brometanol og ! 13,2 g (0,12 M) cyklopentylamin opploses i 100 ml absolutt ! etanol. Opplosningen kokes 24 timer under tilbåkelop. I Opplosningen inndampes til 1/4 av dets opprinnelige volum ! d) 5.5 g (0.02 M) 1-(4-ethylthio-3-methylphenyl)-2-bromoethanol and ! 13.2 g (0.12 M) cyclopentylamine is dissolved in 100 ml absolute ! ethanol. The solution is boiled for 24 hours under reflux. I The solution is evaporated to 1/4 of its original volume
\ og helles derefter til 1-N saltsyre-lbsning. Den vandige i fasen ekstraheres med eter ( 3 x 15 ml ) og gjores alkalisk ; med en mettet losning av natriumkarbonat, og ekstraheres på i nytt med eter (3 x 30 ml). \ and then poured into 1-N hydrochloric acid solution. The aqueous phase is extracted with ether (3 x 15 ml) and made alkaline; with a saturated solution of sodium carbonate, and re-extracted with ether (3 x 30 ml).
i in
;i Eterfasen torkes over magnesiumsulfat og avdampes. Overskudd I av cyklopentylamin avdriver under redusert trykk, og residumet [opptaes i vannfri eter. 4,5 g 1-(4-etyltib-3-métylfenyl)-2-•cyklopentylaminetanol-hydroklorid erholdes ved gjennomstrom-;ning av vannfri hydrogenklorid. ;i The ether phase is dried over magnesium sulfate and evaporated. Excess I of cyclopentylamine evaporates under reduced pressure, and the residue is taken up in anhydrous ether. 4.5 g of 1-(4-ethyltib-3-methylphenyl)-2-•cyclopentylamineethanol hydrochloride is obtained by flowing through anhydrous hydrogen chloride.
;Utbytte: 75%; s.p. (°C): 123 - 124. ;Yield: 75%; s.p. (°C): 123 - 124.
!Dette derivat krystalliserer i metanol-eter. !This derivative crystallizes in methanol-ether.
■ Analyser ■ Analyze
beregnet: :C: 60,80 H: 8,30 N: 4,40 calculated: :C: 60.80 H: 8.30 N: 4.40
funnet: C: 60,60 H: 8,15 N: 4,30 found: C: 60.60 H: 8.15 N: 4.30
t Eksempel 10 t Example 10
1-( 3- klor- 4- metyltiofenyl)- 2- isopropylaminoetanol 1. 13,9 g (0,05 mol) a-brom-3-klor-4-metyltioacetofenon ;i 150 cc isopropanol og 30,6 g aluminiumisopropoksyd (0,15 mol) !i 200 cc isopropanol kokes hver for seg under tilbåkelop. 1-(3-chloro-4-methylthiophenyl)-2-isopropylaminoethanol 1. 13.9 g (0.05 mol) a-bromo-3-chloro-4-methylthioacetophenone; in 150 cc of isopropanol and 30.6 g of aluminum isopropoxide ( 0.15 mol) in 200 cc of isopropanol are boiled separately under reflux.
De to losningene blandes og kokes under tilbåkelop 30 minutter. Efter avkjoling helles produktet til en blanding av vann og is og surgjores med 20% HC1. Presipitåtet avfiltreres og torkes. Man erholder 10 g 1-(3-klor-4-metyltiofenyl)-2-brometanol. Utbytte: 71,4%; s.p.: 86 - 87°C. The two solutions are mixed and simmered for 30 minutes. After cooling, the product is poured into a mixture of water and ice and acidified with 20% HC1. The precipitate is filtered off and dried. 10 g of 1-(3-chloro-4-methylthiophenyl)-2-bromoethanol are obtained. Yield: 71.4%; m.p.: 86 - 87°C.
2. 7 g 1-(3-klor-4-metyltiofenyl)-2-brometanol (0,025 mol) 2. 7 g of 1-(3-chloro-4-methylthiophenyl)-2-bromoethanol (0.025 mol)
i 50 cc etanol behandles med 1,4 g natri.umhydroksyd (0,035 in 50 cc of ethanol is treated with 1.4 g of sodium hydroxide (0.035
mol). Produktet omrores 10 minutter og utspedes derefter med vann. Man ekstraherer med eter og torker over magnesiumsulfat. Opplosningsmidlet avdampes i vakuum og det oljelignende residumet behandles med 100 cc EtOH og 5,9 g isopropylamin (0,1 mol). Produktet omrores ved 50° natten over. Opplosningsmidlet og overskudd av isopropylamin avdampes i vakuum. Det oljelignende residumet krystalliserer efter noen tid (s.p. 111 - 112°C moles). The product is stirred for 10 minutes and then diluted with water. It is extracted with ether and dried over magnesium sulfate. The solvent is evaporated in vacuo and the oil-like residue is treated with 100 cc of EtOH and 5.9 g of isopropylamine (0.1 mol). The product is stirred at 50° overnight. The solvent and excess isopropylamine are evaporated in vacuo. The oil-like residue crystallizes after some time (m.p. 111 - 112°C
efter rekrystallisering i cykloheksan). Den frie basen opploses i eter. Ved gjennomstrømning av torr HCl-gass erholdes 4,88 g 1-(3-klor-4-metyltiofenyl)-2-isopropylaminoetanol-hydroklorid, som rekrystalliseres i metanol-eter-blanding. Smeltepunkt: 139 - 141°C. after recrystallization in cyclohexane). The free base dissolves in ether. By flowing through dry HCl gas, 4.88 g of 1-(3-chloro-4-methylthiophenyl)-2-isopropylaminoethanol hydrochloride is obtained, which is recrystallized in a methanol-ether mixture. Melting point: 139 - 141°C.
Analyser Analyze
% beregnet: C: 55,48 H: 6,98 N: 5,39 % calcd: C: 55.48 H: 6.98 N: 5.39
% funnet: C: 55,47 H: 6,91 N-: 5,27 % found: C: 55.47 H: 6.91 N-: 5.27
Eksempel 11 Example 11
1-( 3- metyl- 4- metyltiofenyl)- 2- isopropylaminoetanol 1. 26,1 g (0,1 mol) 1-(3-metyl-4-metyltiofenyl)-2-brometanol i 150 cc etanol, tilsettes 7,8 g (0,15 mol) kaliumhydroksyd i 100 cc etanol. Blandingen omrores 15 minutter . ved. romtemperatur og det dannede saltet avfiltreres. Blandingen utspedes med vann og ekstraheres flere ganger med eter. Den organiske fasen torkes over magnesiumsulfat og opplosningsmidlet avdampes i vakuum. Den erholdte gule oljen anvendes direkte ved den efterfblgende arbeidsoperasjonen. 2. 5,7 g 3-metyl-4-metyltiofenyletylenoksyd i 30 cc isopropanol tilsettes 7,6 g isopropylamin. Opplosningen kokes under tilbåkelop over natten. Opplosningsmidlet og overskudd av aminet avdampes i vakuum. Den erholdte oljen krystalliserer litt senere. Man erholder 12,1 g 1-(3-metyl-4-metyltiofenyl)-2-isopropylaminoetanol som rekrystalliseres i cykloheksan. S.p.: 89,5 - 90,5°. Hydrokloridet blir rekrystallisert i metanoi-eter-blanding. S.p.: 154 - 155,5°C. 1-(3-methyl-4-methylthiophenyl)-2-isopropylaminoethanol 1. 26.1 g (0.1 mol) 1-(3-methyl-4-methylthiophenyl)-2-bromoethanol in 150 cc ethanol, add 7, 8 g (0.15 mol) of potassium hydroxide in 100 cc of ethanol. The mixture is stirred for 15 minutes. by. room temperature and the formed salt is filtered off. The mixture is diluted with water and extracted several times with ether. The organic phase is dried over magnesium sulphate and the solvent is evaporated in vacuo. The yellow oil obtained is used directly in the subsequent work operation. 2. 5.7 g of 3-methyl-4-methylthiophenylethylene oxide in 30 cc of isopropanol is added to 7.6 g of isopropylamine. The solution is boiled under reflux overnight. The solvent and excess of the amine are evaporated in vacuo. The oil obtained crystallizes a little later. 12.1 g of 1-(3-methyl-4-methylthiophenyl)-2-isopropylaminoethanol is obtained, which is recrystallized in cyclohexane. M.p.: 89.5 - 90.5°. The hydrochloride is recrystallized in a methanol-ether mixture. M.p.: 154 - 155.5°C.
• Analyser • Analyze
% beregnet: C: 56,58 H: 8,04 N: 5,08 % calcd: C: 56.58 H: 8.04 N: 5.08
i% funnet: C: 56,52 H: 8,04 N: 5,28 in% found: C: 56.52 H: 8.04 N: 5.28
i in
1 Eksempel 12 1-( 3- metyl- 4- isopropyltiofenyl)- 2- n- oktylaminoetan61- hydroklorid 1 Example 12 1-(3-methyl-4-isopropylthiophenyl)-2-n-octylaminoethane61-hydrochloride
a) 3-metyl-4-isopropyltioacetofenon erholdes ved å omsette acetylklorid og aluminiumklorid i kloroform med l-metyl-2- a) 3-methyl-4-isopropylthioacetophenone is obtained by reacting acetyl chloride and aluminum chloride in chloroform with 1-methyl-2-
i in
; isopropyltiobenzen ifolge en tidligere beskrevet konvensjonell I fremgangsmåte. |K.p.: 111 - 114°C (0,5 mm). ; isopropylthiobenzene according to a previously described conventional method. |B.p.: 111 - 114°C (0.5 mm).
jb) 3-metyl-4-isopropyltio-a-bromacetofenon erholdes ved ;'brommering av det foregående produkt med trimetylanilihtribromid i o jb) 3-methyl-4-isopropylthio-a-bromoacetophenone is obtained by bromination of the preceding product with trimethylanil tribromide in o
ji tetrahydrofuran ved 0 C. ji tetrahydrofuran at 0 C.
S. p. (°C): 40 - 41°. S.p. (°C): 40 - 41°.
i in
i in
; Analyser !% beregnet:' C: 50,20 H: 5^25 ; Analyze !% calcd:' C: 50.20 H: 5^25
\% funnet: C: 50,05 H: 5,15 \% found: C: 50.05 H: 5.15
c) 3-metyl-4-isopropyltiofenylglyoksal erholdes ved å omsette ,dimetylsulfoksyd med det foregående produkt (36 timer ved c) 3-methyl-4-isopropylthiophenylglyoxal is obtained by reacting dimethylsulfoxide with the preceding product (36 hours at
•romtemperatur). Homogeniteten av den erholdte forbindelsen •room temperature). The homogeneity of the compound obtained
;proves ved hjelp av tynnsjiktskromatografering for den anvendes ;proved by means of thin-layer chromatography before it is used
..jvedden efterfolgende arbeidsoperasjonen. ..jvedden following the work operation.
d) 240 g (1 M) 3-metyl-4-isopropyltiofenyl-glyoksal, 780 g : (6 M) n-oktylaitiin og 1 liter vannfri metanol omrbres 1/2 d) 240 g (1 M) 3-methyl-4-isopropylthiophenyl-glyoxal, 780 g: (6 M) n-octylaithin and 1 liter anhydrous methanol are stirred 1/2
Itime ved romtemperatur. Opplosningen avkjoles til 0°c og 114 g (3 M) natriumborhydrid tilsettes i lopet av 1/2 time. Opplosningen holdes derefter 3 timer ved 20°C. Itime at room temperature. The solution is cooled to 0°c and 114 g (3 M) of sodium borohydride are added over the course of 1/2 hour. The solution is then kept for 3 hours at 20°C.
Losningen inndampes til 1/10 av dets opprinnelige volum og helles til 1 N saltsyre-ldsnihg. Den vandige fasen ekstraheres med eter (3 x 40 ml), derefter gjores alkalisk med 1 N natriumhydroksyd-16sning og siden ekstraheres igjen med eter (3 x ÉO ral). The solution is evaporated to 1/10 of its original volume and poured into 1 N hydrochloric acid solution. The aqueous phase is extracted with ether (3 x 40 ml), then made alkaline with 1 N sodium hydroxide solution and then extracted again with ether (3 x EO ral).
Eterfasen torkes over"magnesiumsulfat og inndampes til torrhet. Overskudd av n-oktylamin avdampes ved redusert trykk. Residumet tåes opp i vannfri eter. Ved gjennomstrømning av torr HCl-gass'erholder^man 153 g 1-(3-metyl-4-isoprppyltio-fenyl)-2-n-oktylaminoetanol-hydroklorid. The ether phase is dried over magnesium sulfate and evaporated to dryness. Excess n-octylamine is evaporated off under reduced pressure. The residue is taken up in anhydrous ether. By passing through dry HCl gas, 153 g of 1-(3-methyl-4-isopropylthio) are obtained -phenyl)-2-n-octylaminoethanol hydrochloride.
Utbytte: 40%; s.p. (°C): 169. Yield: 40%; s.p. (°C): 169.
Analyser Analyze
% beregnet: C: 64,30 H: 9,70 N: 3,75, % calculated: C: 64.30 H: 9.70 N: 3.75,
% funnet: C: 64,20 H: 9,70 N: 3,60 .... % found: C: 64.20 H: 9.70 N: 3.60 ....
Eksempel 13 r ■ • ■...• _ 1- ( 3- metoksy- 4- metyltiofenyl)- 2- tert. butylaminoetanol- hydroklorid a) 3-metoksy-4-metyltioacetofenon erholdes ved å omsette acetylklorid og aluminiumklorid med :l-mGtoksy.-2-rmetyltio-benzen (opplosningsmiddel CHCl^ - 2 timer ved romtemperatur). K.p.: 160° (2 mm). Example 13 r ■ • ■...• _ 1- ( 3- methoxy- 4- methylthiophenyl)- 2- tert. butylaminoethanol hydrochloride a) 3-methoxy-4-methylthioacetophenone is obtained by reacting acetyl chloride and aluminum chloride with :1-mGthoxy.-2-rmethylthio-benzene (solvent CHCl^ - 2 hours at room temperature). K.p.: 160° (2 mm).
Analyser Analyze
% beregnet: C: 61,20 H: 6,15 % calculated: C: 61.20 H: 6.15
% funnet: C: 60,90 H: 5,95 % found: C: 60.90 H: 5.95
Stedet for acétylering bestemmes ved hjelp av det magnetiske The site of acetylation is determined using the magnetic
•atomresonans-spekteret. • the atomic resonance spectrum.
b) 3-metoksy-4-metyltio-a-brpmacetofenon erholdes-ved bromering av det foregående produkt i eter ifolge allerede b) 3-methoxy-4-methylthio-a-brpmacetophenone is obtained by bromination of the preceding product in ether according to already
beskrevet teknikk. . described technique. .
S.p. (°C): 67 - 68.. S. p. (°C): 67 - 68..
Analyser Analyze
% beregnet: C: 43,65 H: 4,05 ■ • • % funnet: C: 43,35 H: 3,95. % calculated: C: 43.65 H: 4.05 ■ • • % found: C: 43.35 H: 3.95.
c) 3-metoksy-4-metyltiofenylglypksar erholdes ved å omsette dimetylsulfoksyd med det foregående produkt (48 timer ved c) 3-methoxy-4-methylthiophenylglypxar is obtained by reacting dimethylsulfoxide with the preceding product (48 hours at
romtemperatur). Produktets -renhet-proves ved hjelp av tynnsjiktskromatograf ering1, og» produktet anvendes , som sådant room temperature). The product's purity is tested using thin-layer chromatography1, and the product is used as such
ved dén efterfSigende arbeidsoperasjonen. at the following work operation.
d) 13,2 g (0,06 M) 3-metoksy-4-metyltiofenyl-glyoksal, 27 g (0,36 M) tert.butylamin og 50 ml vannfri . metanol omrores 30 minutter ved romtemperatur. Opplosningen avkjoles til 0°C og en liten porsjon på 6,8 g (0,18 M) av natriumborhydrid tilsettes. Opplosningen får innta romtemperatur og holdes 2 timer ved denne temperatur. Derefter inndampes den til 1/10 av.dens opprinnelige volum og helles i 1 N saltsyre-losning. d) 13.2 g (0.06 M) 3-methoxy-4-methylthiophenyl-glyoxal, 27 g (0.36 M) tert-butylamine and 50 ml anhydrous . methanol is stirred for 30 minutes at room temperature. The solution is cooled to 0°C and a small portion of 6.8 g (0.18 M) of sodium borohydride is added. The solution is allowed to reach room temperature and kept at this temperature for 2 hours. It is then evaporated to 1/10 of its original volume and poured into 1 N hydrochloric acid solution.
i Den vandige fasen ekstraheres med eter (3x 15 ml). Derefter ; gjores den alkalisk med en 1 N natriumhydroksyd-lSsning i og ekstraheres på nytt med eter (3 x 35 ml). Eterfasen ; torkes over magnesiumsulfat og inndampes til tqrrhet. I Residumet opploses i vannfri eter og ved gjennomstrømning av I vannfri HC1 erholdes 12,3 g 1-(3-metoksy-r4-metyltiofenyl)-2-j tert.butylaminoetanol-hydroklorid. Dette blir rekrystal- i The aqueous phase is extracted with ether (3x 15 ml). After that; it is made alkaline with a 1 N sodium hydroxide solution and re-extracted with ether (3 x 35 ml). The ether phase; dried over magnesium sulfate and evaporated to dryness. I The residue is dissolved in anhydrous ether and by flowing through I anhydrous HCl, 12.3 g of 1-(3-methoxy-4-methylthiophenyl)-2-j tert-butylaminoethanol hydrochloride is obtained. This becomes recrystallized
' lisert i metanol-eter-blanding. ' lysed in methanol-ether mixture.
Utbytte: 60%; s.p. (°C): 192 - 193. Yield: 60%; s.p. (°C): 192 - 193.
1 Analyser 1 Analyze
!% beregnet: C: 54,95 H: 7,90 N: 4,55 !% calculated: C: 54.95 H: 7.90 N: 4.55
% funnet: C: 54,90 H: 7,85 N: 4,45 % found: C: 54.90 H: 7.85 N: 4.45
i in
i in
Eksempel 14 Example 14
1 1- ( 3- metvl- 4- metylsulfonylfenyl)- 2- isopropvlaminoetanol 1 1- ( 3- methyl- 4- methylsulfonylphenyl)- 2- isopropylaminoethanol
<:> a) 3- metyl- 4- metylsulfonylacetofenon <:> a) 3- methyl- 4- methylsulfonylacetophenone
Dette produkt erholdes ved oksydasjon av 3-metyl-4-metyltioacetofenon med hydrogenperoksyd i eddiksyre. This product is obtained by oxidation of 3-methyl-4-methylthioacetophenone with hydrogen peroxide in acetic acid.
Utbytte: 90%; s.p. (°C): 67 - 68 (cykloheksan). Yield: 90%; s.p. (°C): 67 - 68 (cyclohexane).
;b) 3- metvl- 4- metylsulfonyl- a- bromacetofenon ;b) 3-methyl-4-methylsulfonyl-a-bromoacetophenone
■ Erholdes ved bromering av det foregående produkt med brom i eddiksyre. ■ Obtained by bromination of the preceding product with bromine in acetic acid.
Utbytte: 88%; s.p. (°C): 102 - 104 (benzen), Yield: 88%; s.p. (°C): 102 - 104 (benzene),
c) 3- metyl- 4- metylsulfonylfenylglyoksal c) 3- methyl- 4- methylsulfonylphenylglyoxal
Erholdes ved å omsette dimetylsulfoksyd med det foregående produkt. (48 timer ved r.omtemperatur) . Produktets homogenitet proves ved hjelp av tynnsjiktskromatografering. Obtained by reacting dimethylsulfoxide with the preceding product. (48 hours at room temperature) . The homogeneity of the product is tested using thin-layer chromatography.
d) 1-( 3- metyl- 4- metylsulfonylfenyl)- 2- isopropy1ami noetanol 7 g av det .foregående produkt (0,03 M) og 10,8 g isopropylamin d) 1-(3-methyl-4-methylsulfonylphenyl)-2-isopropylaminoethanol 7 g of the previous product (0.03 M) and 10.8 g of isopropylamine
(0,18 M) i lOO ml metanol tilsettes, langsomt under omroring ved en temperatur på 0 - 10°C .3 g... natriumborhydrid. Omroringen fortsettes ennå 3 timer ved denne temperatur. Derefter avdampes opplosningsmidlet og overskudd av amin i vakuum. Residumet behandles med vann og ekstraheres med eter. Den organiske fasen torkes over magnesiumsulfat, og ved gjennom-strømning av torr HCl-gass erholdes 3,2 g av produktet som renses ved rekrystallisering i isopropanol. S.p. (°C): 182 - 183. (0.18 M) in 100 ml of methanol is added, slowly with stirring at a temperature of 0 - 10°C. .3 g... of sodium borohydride. Stirring is continued for a further 3 hours at this temperature. The solvent and excess amine are then evaporated in vacuo. The residue is treated with water and extracted with ether. The organic phase is dried over magnesium sulphate, and by flowing through dry HCl gas, 3.2 g of the product is obtained, which is purified by recrystallization in isopropanol. S. p. (°C): 182 - 183.
Analyser Analyze
% beregnet: C: 50,72 H: 7,20 N: 4,55 % calculated: C: 50.72 H: 7.20 N: 4.55
% funnet: C: 50,55 H: 7,30 N: 4,35 % found: C: 50.55 H: 7.30 N: 4.35
Eksempel 15 1-( 3- klor- 4- metyltiofenyl)- 2- N-( 1- fenyl- 2- aminopropanol) etanol a) 93 g aluminiumklorid i 380 ml vannfri kloroform tilsettes 60 g acetylklorid, og derefter tilsettes langsomt 92 g o-klortioanisol ved en temperatur som holdes ved 10°. Produktet omrores ennå 2 timer ved romtemperatur., Derefter erholdes efter vanlig behandling 97,2 g 3-klor-4-metyltioacetofenon. K.p. = 142 - 146 (0,7 mm). S.p. (°C): 49,5 - 50,5; utbytte: 83,6%. b) 52 g 3-klor-4-metyltioacetofenon i 250 ml vannfri eter tilsettes 41,6 g brom. Tilsetningen skjer ved 20°C og ved Example 15 1-(3-chloro-4-methylthiophenyl)-2-N-(1-phenyl-2-aminopropanol)ethanol a) 93 g aluminum chloride in 380 ml anhydrous chloroform is added to 60 g acetyl chloride, and then 92 g o -chlorothioanisole at a temperature maintained at 10°. The product is stirred for a further 2 hours at room temperature. Then, after the usual treatment, 97.2 g of 3-chloro-4-methylthioacetophenone is obtained. K.p. = 142 - 146 (0.7 mm). S. p. (°C): 49.5 - 50.5; yield: 83.6%. b) 52 g of 3-chloro-4-methylthioacetophenone in 250 ml of anhydrous ether is added to 41.6 g of bromine. The addition takes place at 20°C and at
en langsom strom av nitrogen gjennom losningen. Derefter tilsettes 200 ml petroleter, og det erholdte presipitåtet avfiltreres og vaskes med en 10%'ig vandig bikarbonatlosning. Efter torking erholdes 60,4 g 3-klor-4-metyltio-a-bromacetofenon. S.p. (°C): 84-86; utbytte: 83,5%. a slow stream of nitrogen through the solution. 200 ml of petroleum ether are then added, and the precipitate obtained is filtered off and washed with a 10% aqueous bicarbonate solution. After drying, 60.4 g of 3-chloro-4-methylthio-α-bromoacetophenone are obtained. S. p. (°C): 84-86; yield: 83.5%.
c) 28 g 3-klor-4-metyltio-a-bromacetofenon og 215 ml dimetylsulfoksyd omrores 36. timer ved.romtemperatur. Opplos-i hingén helles til is og ekstraheres med eter. Den organiske c) 28 g of 3-chloro-4-methylthio-a-bromoacetophenone and 215 ml of dimethyl sulfoxide are stirred for 36 hours at room temperature. The dissolved solution is poured into ice and extracted with ether. The organic
fasen torkes over magnesiumsulfat, og derefter avdampes ! opplosningsmidlet i vakuum. 22,1 g gul olje erholdes og I denne krystalliserer raskt. the phase is dried over magnesium sulfate, and then evaporated ! the solvent in vacuo. 22.1 g of yellow oil is obtained and this crystallizes quickly.
, i ... , in ...
i • i 3-klor-4-metyltiofénylglyoksal, hvis homogenitet proves ved ! hjelp av tynnsjiktskromatografering, anvendes som sådan i • i 3-chloro-4-methylthiophenylglyoxal, whose homogeneity is proven by ! using thin-layer chromatography, is used as such
j ved den efterfolgende arbeidsoperasjonen. j in the subsequent work operation.
; d) 7 g 3-klbr-4-metyltiofenylglyoksal (0,033 M) i 50 ml etanol Stilsettes 37,4 g 1-fenyl-2-aminopropanol-hydroklorid (0,2 M). SDerefter tilsettes langsomt 4,4 g natriumborhydrid under omror-; ing og avkjoling i vanribad. Produktet omrores ytterligere over j natten ved romtemperatur. Derefter avdampes alkohol og ;overskudd av amin i vakuum. Residumet taes opp i vann og ; d) 7 g of 3-chloro-4-methylthiophenylglyoxal (0.033 M) in 50 ml of ethanol Add 37.4 g of 1-phenyl-2-aminopropanol hydrochloride (0.2 M). Then slowly add 4.4 g of sodium borohydride while stirring; ing and cooling down in a water bath. The product is stirred further overnight at room temperature. Alcohol and excess amine are then evaporated in a vacuum. The residue is taken up in water and
■ekstraheres med eter. Den organiske fasen vaskes med vann og Itorkes over magnesiumsulfat. Ved gjennomstromning av torr iHCl-gass erholdes 2,7 g hydroklorid. ■extracted with ether. The organic phase is washed with water and dried over magnesium sulfate. When dry iHCl gas is passed through, 2.7 g of hydrochloride is obtained.
Utbytte: 33%. En analytisk prove rekrystalliseres i metanol-'eter-blanding. Yield: 33%. An analytical sample is recrystallized in a methanol-ether mixture.
;S.p. (°C): 212,5 - 213,5. ; (°C): 212.5 - 213.5.
' Analyser ' Analyze
,% beregnet: C: 55,67 H: 5,97 N: 3,61 ,% calculated: C: 55.67 H: 5.97 N: 3.61
<!>% funnet: C: 55,85 H: 5,75 N: 3,45 <!>% found: C: 55.85 H: 5.75 N: 3.45
t t
■ Eksempel 16 ■ Example 16
^ 1- ( 3- metyl- 4- metyltiofenyl)- 2- sek. butylaminoetanol ^ 1-( 3- methyl- 4- methylthiophenyl)- 2- sec. butylaminoethanol
<12,7 g (0,06 M) 3-metyl-4-metyltiofénylglyoksal og 21,9 g sek.-butylamin i lOO ml metanol avkjbles til 10°C og tilsettes langsomt 6,8 g natriumborhydrid. Opplosningen blir derefter bragt til romtemperatur og holdt 2 timer ved nevnte temperatur. Opplosningen inndampes til 1/4 av dets opprinnelige voluum 12.7 g (0.06 M) of 3-methyl-4-methylthiophenylglyoxal and 21.9 g of sec.-butylamine in 100 ml of methanol are cooled to 10° C. and 6.8 g of sodium borohydride are slowly added. The solution is then brought to room temperature and held for 2 hours at said temperature. The solution is evaporated to 1/4 of its original volume
og surgjbres med IN HC1. Den vandige fasen vaskes med eter og gjbres alkalisk med 20%'ig NajSO^'-. Produktet ekstraheres med eter, torkes over magnesiumsulfat og inndampes. Den oljelignende rest taes opp med vannfritt eter og man erholder 1- (3-metyl-4-metyltiofenyl)-2-sek.butyiaminoetanol-hydroklorid ved gjennomstrømning av torr HCl-gass. and surgjbres with IN HC1. The aqueous phase is washed with ether and rendered alkaline with 20% NajSO 4 -. The product is extracted with ether, dried over magnesium sulphate and evaporated. The oil-like residue is taken up with anhydrous ether and 1-(3-methyl-4-methylthiophenyl)-2-sec.butylaminoethanol hydrochloride is obtained by flowing through dry HCl gas.
S.p. (°C): 123 124 (MeOH-eter) S. p. (°C): 123 124 (MeOH ether)
Analyser Analyze
% beregnet:. C: 58,00 H: 8,20 N: 4,65 % calculated:. C: 58.00 H: 8.20 N: 4.65
% funnet: C: 57,90 H: "8,20 N: 4,55 % found: C: 57.90 H: 8.20 N: 4.55
Eksempel 17 Example 17
1-( 3- etvl- 4- metyltlofenyl)- 2- i sopropylaminoetanol 20,6 g 3-etyl-4-metyltiofénylglyoksal (0,1 M) og 17,7 g isopropylamin i 100 ml metanol hydreres i nærvær av 0,1 g platinaoksyd (normalt trykk og temperatur). Opplosningsmidlet og overskudd av amin avdampes i vakuum. Residumet taes opp 1-(3-ethyl-4-methylthiophenyl)-2-isopropylaminoethanol 20.6 g of 3-ethyl-4-methylthiophenylglyoxal (0.1 M) and 17.7 g of isopropylamine in 100 ml of methanol are hydrated in the presence of 0.1 g platinum oxide (normal pressure and temperature). The solvent and excess amine are evaporated in vacuo. The residue is taken up
i vannfri eter og hydrokloridet erholdes ved gjennomstrømning av torr HCl-gass. in anhydrous ether and the hydrochloride is obtained by passing through dry HCl gas.
S.p. (°C).: 109 - 110 (MeOH-eter). S. p. (°C).: 109 - 110 (MeOH-ether).
Analyser Analyze
% beregnet: C: 58,05 H: 8,35 N: 4,80 % calculated: C: 58.05 H: 8.35 N: 4.80
% funnet: C: 58,05 H: 8,40 N: 4,75 % found: C: 58.05 H: 8.40 N: 4.75
Eksempel 18 Example 18
l-( 3- etyl- 4- metylti ofenyl)- 2- s ek. butylami noetanol 10,3 g 3-etylr4-metyltiofénylglyoksal (0,05.M) 1-(3-ethyl-4-methylthiofenyl)-2- s eq. butylaminoethanol 10.3 g 3-ethyl 4-methylthiophenylglyoxal (0.05.M)
og 10,95: g sek>butylamin i 100 ml absolutt etanol hydreres ved normalt trykk og temperatur i nærvær av 0,1.g platinoksyd. Opplosningsmidlet og overskudd av amin avdampes i vakuum. Residumet taes opp i vannfri eter og 10,6 g hydroklorid erholdes ved gjennomstromning av HCl-gass (utbytte: 71%). S.p. (°C): 108 - 109 (MeOH-eter). and 10.95 g of sec-butylamine in 100 ml of absolute ethanol are hydrated at normal pressure and temperature in the presence of 0.1 g of platinum oxide. The solvent and excess amine are evaporated in vacuo. The residue is taken up in anhydrous ether and 10.6 g of hydrochloride is obtained by passing through HCl gas (yield: 71%). S. p. (°C): 108 - 109 (MeOH-ether).
Analyser ... Analyze...
% beregnet:: C: 59,30. H: 8,60 N: 4,60 % calculated:: C: 59.30. H: 8.60 N: 4.60
% funnet: C: 59,15 H: 8,65 N: 4,50 % found: C: 59.15 H: 8.65 N: 4.50
Eksempel 19 1-( 4- n- butyltio- 3- metylfenyl)- 2- ( 3- metoksypropylamino) etanol 11,8 g 4-n-butyltio-3-metylfénylglyoksal (0,05 M) og. 26,5 g 3-metoksypropylamin i 80.ml metanol tilsettes langsomt ved en temperatur på O - 5°C. 4,8 g natriumborhydrid. Efter tilsethin-! gen får produktet innta romtemperatur, og det omrores ytter-ii ligere 2 timer. Avskilling av produktet gjores ifolge I tidligere beskrevne måte. Man erholder 10,4 g hydroklorid (utbytte: 62%). S.p. (°C): 109 -110 (benzen-petroleter). Example 19 1-(4-n-butylthio-3-methylphenyl)-2-(3-methoxypropylamino)ethanol 11.8 g 4-n-butylthio-3-methylphenylglyoxal (0.05 M) and. 26.5 g of 3-methoxypropylamine in 80 ml of methanol are added slowly at a temperature of 0 - 5°C. 4.8 g of sodium borohydride. After tilsethin-! The product is then allowed to reach room temperature, and it is stirred for a further 2 hours. Separation of the product is done according to the method previously described. 10.4 g of hydrochloride are obtained (yield: 62%). S. p. (°C): 109 -110 (benzene-petroleum ether).
! Analyser ! Analyze
|% beregnet: C: 58,87 H: 8,69 N: 4,02 |% calcd: C: 58.87 H: 8.69 N: 4.02
i !% funnet: C: 58,59 H: 8,55 N: 3,,95 in !% found: C: 58.59 H: 8.55 N: 3.95
- Eksempel 20 - Example 20
j 1- ( 3- metvl- 4- metyltiofenyl) - 2- ( 1, 2- dimetylpropylamino) etanol-I hydroklorid ..... a) 259 g (1 M) a-brom-3-metyl-4-metyltio-acetofenon opploses •i 1500 ml kloroform. 140 g (1 M) heksametylen-tetramin til-i settes og opplosningen omrores 2 timer ved vanlig temperatur, i Bunnfallet filtreres og vaskes med vann og derefter med ; aceton. 248 g erholdes. Utbytte: 60%. j 1-(3-methyl-4-methylthiophenyl)-2-(1,2-dimethylpropylamino)ethanol-I hydrochloride ..... a) 259 g (1 M) α-bromo-3-methyl-4-methylthio -acetophenone is dissolved in 1500 ml of chloroform. 140 g (1 M) of hexamethylene tetramine are added and the solution is stirred for 2 hours at ordinary temperature, the precipitate is filtered and washed with water and then with ; acetone. 248 g are obtained. Yield: 60%.
; b) 411 g (1 M) av det foregående bunnfall opploses i 900 ml 'etanol som inneholder 450 ml konsentrert saltsyre.. ■ Opp-ilosningen omrores natten over ved vanlig temperatur. I Ammoniumkloridet avfiltreres og vaskes med etylalkohol. Filtratet inndampes til torrhet. 186 g oc-amino-3-metyl-4-I metyltioacetofenon-hydroklorid (utbytte: 80%) isoleres, ; b) 411 g (1 M) of the previous precipitate is dissolved in 900 ml of ethanol containing 450 ml of concentrated hydrochloric acid. ■ The solution is stirred overnight at normal temperature. I The ammonium chloride is filtered off and washed with ethyl alcohol. The filtrate is evaporated to dryness. 186 g of α-amino-3-methyl-4-I methylthioacetophenone hydrochloride (yield: 80%) are isolated,
.som rekrystalliseres i metanol-eter-blanding. .which is recrystallized in a methanol-ether mixture.
' c) 116 g (0,5 M) oc-amino-3-metyl-4-metyltio-acetofenon-jhydroklorid opploses i 1 liter metanol. Opplosningen avkjoles i til 0°C og 39 g (1 M) natriumborhydrid tilsettes i lopet av c) 116 g (0.5 M) of α-amino-3-methyl-4-methylthio-acetophenone hydrochloride are dissolved in 1 liter of methanol. The solution is cooled to 0°C and 39 g (1 M) sodium borohydride is added in the course of
15 minutter. Opplosningen omrores to timer ved vanlig I temperatur. Opplosningen inndampes til en tiendedel av dets '.opprinnelige volum og helles til vann, derefter gjor man ilosningen alkalisk med I N natriumhydroksyd-ldsning og '■■ ekstraherer med eter. • Eterfasen torkes over magnesiumsulfat og, inndampes til torrhet. ;Man isolerer 54 g 1-(3-metyl-4-metyltiofenyl)-2-amihoetanol. 15 minutes. The solution is stirred for two hours at normal temperature. The solution is evaporated to one-tenth of its original volume and poured into water, then the solution is made alkaline with 1 N sodium hydroxide solution and extracted with ether. • The ether phase is dried over magnesium sulphate and evaporated to dryness. 54 g of 1-(3-methyl-4-methylthiophenyl)-2-amichoethanol are isolated.
Hydrokloridet fåes ved gjennomstromning av torr HCl-gass The hydrochloride is obtained by passing through dry HCl gas
i en eter-losning av basen. Hydrokloridet rekrystalliseres 1 -metanol-eter—blanding. in an ether solution of the base. The hydrochloride is recrystallized 1 -methanol-ether mixture.
S.p. (°C) 187 - 188°. S. p. (°C) 187 - 188°.
Analyser Analyze
% beregnet: C: 51,40 H: 6,90 N: 6,00 % calculated: C: 51.40 H: 6.90 N: 6.00
funnet: C: 51,30 H: 6,85 N: 5,80 found: C: 51.30 H: 6.85 N: 5.80
d) 19,7 g 1-(3-metyl-4-metyltiofenyl)-2-aminoetanol (0,1 M) opploses i 50 ml metylisopropylketon. Opplosningen oppvarmes d) 19.7 g of 1-(3-methyl-4-methylthiophenyl)-2-aminoethanol (0.1 M) are dissolved in 50 ml of methyl isopropyl ketone. The solution is heated
under tilbåkelop 5 timer. Overskudd av keton destilleres og residumet opploses i 30 ml metanol. Denne losningen avkjoles til 0°C og tilsettes i lopet av 15 minutter 0,8 g (0,2 M) natrium-borhydrid. Losningen bringes til normal temperatur, og efter 2 timer inndampes den til en fjerdedel av dets opprinnelige volum og resten helles til vann. Man gjor alkalisk med en 20%'lg NaOH-losning og ekstraherer med eter. Eterfasen torkes over magnesiumsulfat. Ved gjennomstromning av torr HCl-gass fåes 15 g 1-(3-metyl-4-metyltiofenyl)-2-(1,2-dimetylpropylamino) etanol-hydroklorid. during return run 5 hours. Excess ketone is distilled and the residue is dissolved in 30 ml of methanol. This solution is cooled to 0°C and 0.8 g (0.2 M) sodium borohydride is added over 15 minutes. The solution is brought to normal temperature, and after 2 hours it is evaporated to a quarter of its original volume and the rest is poured into water. It is made alkaline with a 20% lg NaOH solution and extracted with ether. The ether phase is dried over magnesium sulfate. By passing through dry HCl gas, 15 g of 1-(3-methyl-4-methylthiophenyl)-2-(1,2-dimethylpropylamino) ethanol hydrochloride are obtained.
S.p. (°C): 177 - 178 (metanol-eter). S. p. (°C): 177 - 178 (methanol-ether).
Analyser Analyze
% beregnet: C: 59.30 H: 8,60 N: 4,60 % calculated: C: 59.30 H: 8.60 N: 4.60
% funnet: C: 59,OO H: 8,45 N: 4,45 % found: C: 59.00 H: 8.45 N: 4.45
Eksempel 21 Example 21
1-( 3- metvl- 4- metyltiofenyl)- 2- isopropylaminoetanol- hydroklorid 19,7 g (0,1 M) 1-(3-metyl-4-metyltiofenyl)-2-aminoetanol opploses i 50 ml aceton. Opplosningen oppvarmes under tilbåkelop 5 timer. Acetonet avdestilleres pg residumet opploses i 30 ml metanol. Denne opplosningen avkjoles til 0°C,og tilsettes i lopet av 15 minutter 0,8 g (0,2 M) natriumborhydrid. Losningen bringes til romtemperatur og holdes 2 timer ved denne temperatur. Losningen inndampes til 1/4 av dens opprinnelige volum og helles til vann. Den vandige fasen gjores alkalisk med natriumhydroksyd-losning og ekstraheres 1-(3-methyl-4-methylthiophenyl)-2-isopropylaminoethanol hydrochloride 19.7 g (0.1 M) 1-(3-methyl-4-methylthiophenyl)-2-aminoethanol is dissolved in 50 ml of acetone. The solution is heated under reflux for 5 hours. The acetone is distilled off because the residue is dissolved in 30 ml of methanol. This solution is cooled to 0°C and 0.8 g (0.2 M) sodium borohydride is added over 15 minutes. The solution is brought to room temperature and kept at this temperature for 2 hours. The solution is evaporated to 1/4 of its original volume and poured into water. The aqueous phase is made alkaline with sodium hydroxide solution and extracted
med eter. Eterfasen torkes over magnesiumsulfat. Ved gjennomstromning iav torr HCl-gass erholdes 11 g 1-(3-metyl-4- with ether. The ether phase is dried over magnesium sulfate. By passing dry HCl gas through, 11 g of 1-(3-methyl-4-
metyltiofenyl)-2-isoprbpylaminoétanol-hydroklorid. methylthiophenyl)-2-isopropylaminoethanol hydrochloride.
Utbytte: 40%; s.p. (°C) : 154,5 - 155,5. Yield: 40%; s.p. (°C) : 154.5 - 155.5.
i in
I Analyser In Analyses
I % beregnet: C: 56,58 H: 8,04 N: 5,08 In % calculated: C: 56.58 H: 8.04 N: 5.08
„! % funnet: C: 56,60 H: 8,10 N: 5,IO “! % found: C: 56.60 H: 8.10 N: 5.10
i ........ in ........
j j
I Eksempel 22 In Example 22
1- ( 4- n- butvltio- 3- metylf enyl) - 2- N, N- dipropylamihoetanol i 3,8 g litiumaluminiumhydrid (0,1 M) i 50 ml vannfri eter , tilsettes langsomt under omroring 3,37 g N,N-dipropyl-4-n- 1-(4-n-butylthio-3-methylphenyl)-2-N,N-dipropylamihoethanol in 3.8 g of lithium aluminum hydride (0.1 M) in 50 ml of anhydrous ether, add slowly while stirring 3.37 g of N, N-dipropyl-4-n-
I IN
i butyltio-3-metylmandelamid (O,1 M) i 50 ml vannfri eter. ,| Efter tilsetningen omrores produktet ytterligere 30 minutter I ved romtemperatur. Derefter tilsettes langsomt 3,3 ml vann og 3,3 imi vandig opplosning av natriumhydroksyd og derefter ytterligere j 10 ml vann. Efter filtrering torkes den organiske fasen over I magnesiumsulfat. Ved gjennomstromning av torr HCl-gass jerholdes 2,44 g 1- (4-n-butyltio-3-metylfenyl)-2-N,N-dipropylaminoetanol-hydroklorid. Utbytte: 72%. S.p. (°C): 144 - 145 (aceton-petroleter). in butylthio-3-methylmandelamide (0.1 M) in 50 ml of anhydrous ether. ,| After the addition, the product is stirred for a further 30 minutes at room temperature. 3.3 ml of water and 3.3 ml of an aqueous solution of sodium hydroxide are then slowly added and then a further 10 ml of water. After filtration, the organic phase is dried over I magnesium sulphate. By passing through dry HCl gas, 2.44 g of 1-(4-n-butylthio-3-methylphenyl)-2-N,N-dipropylaminoethanol hydrochloride are retained. Yield: 72%. S. p. (°C): 144 - 145 (acetone-petroleum ether).
I IN
i Analyser in Analyzes
,% beregnet: C: 63,39 H: 9,52 N: 3,89 ,% calculated: C: 63.39 H: 9.52 N: 3.89
!% funnet: C: 63,21 H: 9,62 N: 3,67 !% found: C: 63.21 H: 9.62 N: 3.67
i in
Eksempel 23 ] 1-( 3- metvl- 4- metyltiofenyl)- 2- isopropylaminoetanoloksalat !l,20 g 1-(3-metyl-4-metyltiofenyl)-2-isopropylaminoetanol i 40 ml eter tilsettes dråpevis under omroring 0,45 g oksalsyre i 50 ml eter. Presipitatet avfiltreres og vaskes med eter, Example 23 ] 1-(3-methyl-4-methylthiophenyl)-2-isopropylaminoethanol oxalate 1.20 g 1-(3-methyl-4-methylthiophenyl)-2-isopropylaminoethanol in 40 ml of ether is added dropwise while stirring 0.45 g oxalic acid in 50 ml of ether. The precipitate is filtered off and washed with ether,
■derefter krystalliseres i metanol-eter-blanding. ■ then crystallized in a methanol-ether mixture.
is.p. (°C): 165,5 - 167,5. is.p. (°C): 165.5 - 167.5.
1-( 3- metyl- 4- metyltiofenyl)- 2- isopropylaminoetanolglukonat 1,20 g 1-(3-metyl-4-metyltiofenyl)-2-isoprbpylaminoetanol i 40 ml vann tilsettes 1,96 ml av en 50%'ig glukonsyre-lbsning. Blandingen varmes på vannbad 1 time ved 70°. Derefter gjores 1-(3-methyl-4-methylthiophenyl)-2-isopropylaminoethanol gluconate 1.20 g of 1-(3-methyl-4-methylthiophenyl)-2-isopropylaminoethanol in 40 ml of water is added to 1.96 ml of a 50% gluconic acid -lbsning. The mixture is heated in a water bath for 1 hour at 70°. Then done
losningen lyofil (2.,18 <j av det. erholdte saltet er loselig i 5 ml vann og gi r et -pH på 4,6). the solution is lyophilic (2.18 <j of the salt obtained is soluble in 5 ml of water and gives a -pH of 4.6).
Eksempel 24 Example 24
1- ( 3- metyl-" 4- me ty lti of enyl) - 2— isopropylaminoetanollaktat 1,2 g 1-(3-metyl-4-metyltiofenyl)-2-isopropylaminoetanol i 32 inl vann tilsettes 0,53 g av en 85%'ig vandig melkesyre-opplosning. Produktet oppvarmes på vannbad i 2 timer ved 50°. Derefter gjores opplosningen lyofil. (1,55 g av det erholdte saltet er opploselig i 5 ml vann). 1-(3-methyl-" 4-methylethyl of enyl)-2- isopropylaminoethanol lactate 1.2 g of 1-(3-methyl-4-methylthiophenyl)-2-isopropylaminoethanol in 32 inl of water is added to 0.53 g of a 85% aqueous lactic acid solution. The product is heated in a water bath for 2 hours at 50°. The solution is then lyophilized. (1.55 g of the obtained salt is soluble in 5 ml of water).
0 0
Eksempel 25 Example 25
1-( 4- isopropyltiofenyl- 2- n- oktylaminopropanol 57 g av a-brom-4-isopropyltiopropiofenon (0,2M), 26 g n-oktylamin (0,2 M) og 300 ml metanol tilbakelopsbehandles i 1-(4-isopropylthiophenyl-2-n-octylaminopropanol) 57 g of α-bromo-4-isopropylthiopropiophenone (0.2 M), 26 g n-octylamine (0.2 M) and 300 ml of methanol are refluxed in
3 timer. Opplosningen kjoles til ca. 0°C og under omroring 3 hours. The solution is stirred until approx. 0°C and under stirring
tilsettes det en opplosning av 8 g NaBH^ i 100 ml "vann. Omroringen fortsettes over natten ved romtemperatur og metanolen fordampes. Resten fortynnes _med 200 ml vann og ekstraheres med metylenklorid. Den oxganiske fase torkes på MgS04, resten omkrystalliseres i. n-pentan eller i en metanol-vann-blanding..40,2 g oppnås. Utbytte: 60%. Smeltepunkt (°C): a solution of 8 g of NaBH^ in 100 ml of water is added. The stirring is continued overnight at room temperature and the methanol is evaporated. The residue is diluted with 200 ml of water and extracted with methylene chloride. The oxalic phase is dried over MgSO 4 , the residue is recrystallized in n-pentane or in a methanol-water mixture..40.2 g is obtained. Yield: 60%. Melting point (°C):
62-63 og 232-234 for hydrokloridet. 62-63 and 232-234 for the hydrochloride.
Prosent analyse: Percentage Analysis:
Beregnet % -C 71,46, H 10,45, N 4,15 Funnet % C 71,40, H 10,30, "N 4,20. Calculated % -C 71.46, H 10.45, N 4.15 Found % C 71.40, H 10.30, "N 4.20.
Erytrokonfigurasjonen av produktet vises ved undersøkelser av det nukleare, magnetiske resonans-spektrum. The erythro configuration of the product is shown by examination of the nuclear magnetic resonance spectrum.
Eksempel 26 Example 26
1-( 4- isopropyltiofenyl)- 2- n- oktylaminopropanol 1-(4-isopropylthiophenyl)-2-n-octylaminopropanol
a) . Til 28,7 g cc-brom-4-isopropyltiopropiofenon (0,1 M) i 100 ml isopropanol tilsettes hurtig 14,2 g n-oktylamin under a) . To 28.7 g of cc-bromo-4-isopropylthiopropiophenone (0.1 M) in 100 ml of isopropanol, quickly add 14.2 g of n-octylamine under
omroring, og blandingen holdes ved 80°C i 1 time. Opplosningsmidlet fordampes under vakuum, resten fortynnes med 1 liter stirring, and the mixture is kept at 80°C for 1 hour. The solvent is evaporated under vacuum, the residue is diluted with 1 liter
eter og får henstå over natten i kjoleskap. Fel-^ ether and leave overnight in a refrigerator. Wrong-^
lingen som oppnås filtreres og torkes. Det oppnås således 25 g a-n-oktylamino-4-isopropyltioprdpiofénonhydrobromid. Utbytte: the solution obtained is filtered and dried. 25 g of a-n-octylamino-4-isopropylthiopridepiophenone hydrobromide are thus obtained. Dividend:
60%-Smeltepunkt (°C) : 162-164. 60%-Melting point (°C) : 162-164.
Prosent analyse: Percentage Analysis:
% beregnet: C 57,70, H 8,25, N 3,35 % calculated: C 57.70, H 8.25, N 3.35
% funnet: C 57,85 H 8,05 N 3,10 % found: C 57.85 H 8.05 N 3.10
Reaksjonen kan likeledes utfores i acetonitril og metanol. b) 41,6 g av forannevnte produkt (0,1 M) i 200 ml metanol kjoles "i et isbad til 0°C. Det tilsettes dråpevis under omroring en opplosning av 4,1 g NaBH^ i 50 ml vann pg 2 ml 5%'s NaOH, og derpå rores det om i 2 timer ved romtemperatur. Metanolen fordampes under vakuum, den fortynnes med 200 ml vann, den ekstraheres med metylenklorid ellér eter, den organiske fase torkes over MgSO^ og opplosningsmidlet fordampes under vakuum. Den oljeaktige rest som oppnås storknér hurtig og omkrystalliseres i pentan. 33,2 g oppnås på denne måte. Utbytte: 90% - Smeltepunkt (°C): 62-63. The reaction can also be carried out in acetonitrile and methanol. b) 41.6 g of the above-mentioned product (0.1 M) in 200 ml of methanol are cooled in an ice bath to 0°C. A solution of 4.1 g of NaBH^ in 50 ml of water is added dropwise while stirring at 2 ml 5% NaOH, and then it is stirred for 2 hours at room temperature. The methanol is evaporated under vacuum, it is diluted with 200 ml of water, it is extracted with methylene chloride or ether, the organic phase is dried over MgSO^ and the solvent is evaporated under vacuum. oily residue which is obtained very quickly and recrystallized in pentane 33.2 g is obtained in this way Yield: 90% - Melting point (°C): 62-63.
Eksempel 27 1-( 4- metyltiofenyl)- 2- n- oktylaminopropanol Til 52 g ct-brom-4-metyltiopropiofenon (0,2 M) i 200 ml etanol tilsettes hurtig under omroring 26 g n-oktylamin (0,2 M) og det tilbakelopsbehandles i 4 timer. Blandingen kjoles til 0°C og.8 g NaBH^ tilsettes gradvis idet temperaturen holdes mellom 0 og 5°C. Omroring utfores over natten ved romtemperatur og opplosningsmidlet fordampes under vakuum. Resten fortynnes med 200 ml vann,.surgjqres med .20 % HC1, vaskes to ganger med 100 ml eter, alkaliseres med 20% NaOH og ekstraheres med eter. Den organiske fase torkes over MgS04 og filtreres. En strom av torr gassholdlg saltsyre fores gjennom den eteriske opplosning og den oppnådde felling filtreres. Denne sistnevnte omkrystalliseres i en blanding av aceton og metanol. 43 g l-(4-metyltiofenol)-2-n-oktylaminopropanolhydroklorid oppnås. Example 27 1-(4-methylthiophenyl)-2-n-octylaminopropanol To 52 g of ct-bromo-4-methylthiopropiophenone (0.2 M) in 200 ml of ethanol, 26 g of n-octylamine (0.2 M) are quickly added while stirring. and it is refluxed for 4 hours. The mixture is cooled to 0°C and 8 g of NaBH^ is added gradually, keeping the temperature between 0 and 5°C. Stirring is carried out overnight at room temperature and the solvent is evaporated under vacuum. The residue is diluted with 200 ml of water, acidified with 20% HCl, washed twice with 100 ml of ether, alkalized with 20% NaOH and extracted with ether. The organic phase is dried over MgSO 4 and filtered. A stream of dry gaseous hydrochloric acid is passed through the ethereal solution and the precipitate obtained is filtered. This latter is recrystallized in a mixture of acetone and methanol. 43 g of 1-(4-methylthiophenol)-2-n-octylaminopropanol hydrochloride are obtained.
Utbytte: 62% - Smeltepunkt (°C): 231-232. Yield: 62% - Melting point (°C): 231-232.
Elemeritæranalyse: Elemental analysis:
%~beregnet: C 62,49, H 9,32, N 4,05 %~calculated: C 62.49, H 9.32, N 4.05
% funnet: C 62,70, H 9,40, N 3,95. % found: C 62.70, H 9.40, N 3.95.
Eksempel 28 Example 28
1-( 4- isopropyltiofenyl)- 2- n- oktyiaminopropanol 1-(4-isopropylthiophenyl)-2-n-octylaminopropanol
..29 g a-brom-4-isopropyltiopropiof enon iO ,1 M)., 43r8 g benzyl-oktylamiri (0-, 2 M) og 300 ml vannfritt acetonitril rores om i 20 timer ved-romtemperatur. Fellingen filtreres og den organiske fase fordampes;. Den oppnådde oljeaktige rest tas opp i 200 ml -vannfri eter og det tilsettes dråpevis en opplosning av 4 g H^LiAl i 150 ml vannfri eter. Blandingen tilbakelopsbehandles i 2 timer og det "overskytende hydrrd odelegges ved tilsetningen av "4 ml vann. Den organiske fase filtreres ved å fores gjennom en torr gassholdig strom av saltsyre og det oppnås 38 g 1- (4-isopropyltiof enyl) - 2-benzyloktyl-aminopropanol. Smeltepunkt (0°C)^ 104-105. ..29 g of a-bromo-4-isopropylthiopropiof enone (10.1 M), 43.8 g of benzyl-octylamiri (0-.2 M) and 300 ml of anhydrous acetonitrile are stirred for 20 hours at room temperature. The precipitate is filtered and the organic phase is evaporated. The obtained oily residue is taken up in 200 ml of anhydrous ether and a solution of 4 g of H^LiAl in 150 ml of anhydrous ether is added dropwise. The mixture is refluxed for 2 hours and the excess hydride is removed by the addition of 4 ml of water. The organic phase is filtered by passing through a dry gaseous stream of hydrochloric acid and 38 g of 1-(4-isopropylthiophenyl)-2-benzyloctyl-aminopropanol are obtained. Melting point (0°C)^ 104-105.
Prosent analyse Percentage analysis
% beregnet: C 69,86., H 9,12, N 3,02 56<T>funnét: -C 69,64, H 8,92., N 2,8-7 10 g av forannevnte produkt, 100 ml etanol, 1 g palladium på 10 % karbon og ml konsentrert HC1 hydrogeneres ved romtemperatur og normalt trykk.. % calculated: C 69.86., H 9.12, N 3.02 56<T>found: -C 69.64, H 8.92., N 2.8-7 10 g of the aforementioned product, 100 ml ethanol, 1 g of palladium on 10% carbon and ml of concentrated HC1 are hydrogenated at room temperature and normal pressure..
Opplosningen filtreres og fordampes under vakuum. Etter omkrystallisasjon i metanoleter oppnås således: 7,8 g 4-(isopropyltiofenyl)-2-n-oktylaminopropanolhydrokloricl. Smeltepunkt (0°<C>) : The solution is filtered and evaporated under vacuum. After recrystallization in methanol ether, the following is obtained: 7.8 g of 4-(isopropylthiophenyl)-2-n-octylaminopropanol hydrochloride. Melting point (0°<C>) :
222-224 (under spaltning}. 222-224 (under cleavage}.
Prosent analyse: Percentage analysis:
% beregnet: C 64-, 22, H 5,.70., N 3,74 % calculated: C 64-, 22, H 5.70, N 3.74
% funnet: X: 64,20, H 9,50, N 3,60. % found: X: 64.20, H 9.50, N 3.60.
Produktets treokonfigurasjon vises ved undersokelser av det nukleare, magnetiske resonans-spektrum. The product's triple configuration is shown by examinations of the nuclear magnetic resonance spectrum.
Eksempel 29 Example 29
1-( 4- i sopropylt io fenyl)- 2- n- oktylami nopropano1 1-(4-isopropylthiophenyl)-2-n-octylaminopropano1
a) Til 15 g a-brom-4-isopropyltiopropiofenon i 200 ml metanol kjolt til 0°C tilsettes gradvis under omroring 4,5 g NaBH^. a) To 15 g of a-bromo-4-isopropylthiopropiophenone in 200 ml of methanol cooled to 0°C, gradually add 4.5 g of NaBH^ while stirring.
Omroring utfores i 30 minutter ved romtemperatur og derpå fortynnes det med 200 ml vann og surgjores med 45 % HBr. Ekstraksjon med eter utfores og den organiske fase torkes over MgSO^ og fordampes. 15,6 g av en olje oppnås, hvis homogenitet be-kreftes av CCM og hvilken olje anvendes ved den folgende ar-beidsgang. b) 15 g av forannevnte produkt, 75 ml n-oktylamin og 100 ml absolutt eter bringes til tilbakelopskjbling i 20 timer. Opplosningsmidlet og overskytende amin fordampes under vakuum. Resten behandles med 200 ml 5 % HCl, fellingen filtreres og vaskes med vann bg med diisopropyleter. Omkrystallisasjon utfores i aceton og man oppnår således 10 g 1-(4-isopropyltiofenyl)-2-n-oktylaminopropanolhydroklorid. Utbytte: 51 % (trinn a og b). Smeltepunkt: 222-224°C (under spaltning). Den frie base omkrystalliseres i pentan. Smeltepunkt (°C): 51-52. Stirring is carried out for 30 minutes at room temperature and then it is diluted with 200 ml of water and acidified with 45% HBr. Extraction with ether is carried out and the organic phase is dried over MgSO 4 and evaporated. 15.6 g of an oil is obtained, the homogeneity of which is confirmed by CCM and which oil is used in the following procedure. b) 15 g of the aforementioned product, 75 ml of n-octylamine and 100 ml of absolute ether are refluxed for 20 hours. The solvent and excess amine are evaporated under vacuum. The residue is treated with 200 ml of 5% HCl, the precipitate is filtered and washed with water bg with diisopropyl ether. Recrystallization is carried out in acetone and 10 g of 1-(4-isopropylthiophenyl)-2-n-octylaminopropanol hydrochloride is thus obtained. Yield: 51% (steps a and b). Melting point: 222-224°C (under decomposition). The free base is recrystallized in pentane. Melting point (°C): 51-52.
Prosent analyse: Percentage Analysis:
% beregnet C 71,46, H 10,45, N 4,15 % calculated C 71.46, H 10.45, N 4.15
% funnet C 71,50, H 10,45, N 4,30. % found C 71.50, H 10.45, N 4.30.
Treokonfigurasjonen for produktet vises ved undersokelser av det kjerne-magnetiske resonans-spektrum. The triplet configuration of the product is shown by examination of the nuclear magnetic resonance spectrum.
Eksempel 30 Example 30
8,4 g (0,03 M) I, 5,1 g (0,06 M) piperidin og 100 ml vannfri eter ble rort om over natten ved romtemperatur. Man filtrerer og fordamper filtratet. Oljen som oppnås opploses i 100 ml metanol og man tilsetter etterhvert 2,3 g NaBH4 ved en temperatur på 8.4 g (0.03 M) I, 5.1 g (0.06 M) piperidine and 100 ml anhydrous ether were stirred overnight at room temperature. The filtrate is filtered and evaporated. The oil obtained is dissolved in 100 ml of methanol and 2.3 g of NaBH4 is gradually added at a temperature of
10°C. Etter tilsetning -rbrer man om 2 til 3 timer ved omgivelsestemperatur og deretter fordamper man opplosningsmidlet. Resten fortynnes med vann (lOO ml) og ekstraheres med eter. Den organiske fase torkes over MgSO^ og filtreres. Man forer gjennom gassformet torr HC1 og man oppnår 8,3 g av III som omkrystalliseres fra metanol—eter og deretter fra aceton. Smeltepunkt: 218 - 219°C. 10°C. After addition, the mixture is stirred for 2 to 3 hours at ambient temperature and then the solvent is evaporated. The residue is diluted with water (100 ml) and extracted with ether. The organic phase is dried over MgSO4 and filtered. Gaseous dry HCl is passed through and 8.3 g of III is obtained, which is recrystallized from methanol-ether and then from acetone. Melting point: 218 - 219°C.
Anallyse; Analysis;
% Beregnet: C 52,17; H 6,57; N 4,35 % Calculated: C 52.17; H 6.57; N 4.35
% Funnet: C 52,30;. H 6,70; -N 4,15. % Found: C 52.30;. H 6.70; -N 4.15.
Eksempel 31 Example 31
34 g (Q.,11 M) I, 32 g sek-butylamin 44 M) og 250 ml -acetonitril ro res -om i 24 timer ved omgivelsestemperatur. Man til--setter deretter 250 ml eter og filtrerer. Filtratet fordampes. Den oppnådde olje opploses i 100 ml metanol og man tilsetter etterhvert 8,3 g (0,22 M) NaBH4 ved en temperatur på 0-5°C, og rorer deretter om i 2 timer ved romtemperatur.. Man fordamper opplosningsmidlet, fortynner resten med 200 ml vann og ekstraherer med eter. Den organiske fase torkes over MgSO^ og filtreres. Man forer gjennom torr gassformet HC1 og man får 14,4 g av III som omkrystalliseres fra metanol-eter og deretter fra isopropanol. Smeltepunkt: .193-194., 5°C . 34 g (Q., 11 M) I, 32 g sec-butylamine 44 M) and 250 ml -acetonitrile are stirred for 24 hours at ambient temperature. 250 ml of ether are then added and filtered. The filtrate is evaporated. The oil obtained is dissolved in 100 ml of methanol and added eventually 8.3 g (0.22 M) NaBH4 at a temperature of 0-5°C, and then stir for 2 hours at room temperature. The solvent is evaporated, the residue is diluted with 200 ml of water and extracted with ether. The organic phase is dried over MgSO4 and filtered. Dry gaseous HCl is passed through and 14.4 g of III is obtained, which is recrystallized from methanol-ether and then from isopropanol. Melting point: .193-194., 5°C .
- Analyse: - Analysis:
% Beregnet: C 54,54? H 7,7 2; N 3,98.; % Funnet: C 5 4,51; H 7,76; N 3,-73. Eksempel 32 8 g I (0,025 M)', 4,1 g n-oktylamin (0,025 M) og 25 ml acetonitril tilbakelopsbehandles i 3 timer. Man fordamper deretter opplosningsmidlet og fortynner resten med 25 ml metanol. Man tilsetter etterhvert 1,9 g NaBH^ ved en temperatur på - 5°C, hvoretter man rorer om over natten ved romtemperatur. Man fordamper opplosningsmidlet og fortynner resten med 100 ml vannfri eter. % Calculated: C 54.54? H 7.7 2; N 3.98.; % Found: C 5 4.51; H 7.76; N 3,-73. Example 32 8 g of I (0.025 M), 4.1 g of n-octylamine (0.025 M) and 25 ml of acetonitrile are refluxed for 3 hours. The solvent is then evaporated and the residue diluted with 25 ml of methanol. 1.9 g of NaBH^ are gradually added at a temperature of - 5°C, after which the mixture is stirred overnight at room temperature. The solvent is evaporated and the residue is diluted with 100 ml of anhydrous ether.
Man surgjor med en eterisk saltsyreopplosning og filtrerer fellingen som omkrystalliseres fra metanol-eter. Man oppnår således 3 g av III. Smeltepunkt: 2lO-212°C. Acidify with an ethereal hydrochloric acid solution and filter the precipitate which is recrystallized from methanol-ether. 3 g of III is thus obtained. Melting point: 2lO-212°C.
Analyse: Analysis:
% Beregnet: C 64,99; H 9,87; N 3,61; % Calculated: C 64.99; H 9.87; N 3.61;
% Funnet: C 65,10; H 9,95; N 3,45. % Found: C 65.10; H 9.95; N 3.45.
Eksempel 33 Example 33
55 g I (0,2-M) , 26 g n-oktylamin \ Q_, 2 M) og 200 ml etanol tilbakelopsbehandles i 4 -timer-.: Man kjoler av op<p>losningen til +5°C og tilsetter etterhvert 8 g NaBH^ og-rorer deretter om i 12 timer ved -romtemperatur. Man fordamper -opplosningsmidlet og fortynner resten med 200 :ml -vann og ekstraherer med -eter. ^en eteriske fase torkes over MgSQ^, filtreres og .etter gjennom-foring av torr gassformet HCl oppnår man 35 g av III som omkrystalliseres fra metanol-aceton. • -Smeltepunkt: 230-232 oC. Analyse: % Beregnet: C 63,39; :H 9,52; N 3,89; 55 g I (0.2-M), 26 g n-octylamine \Q_, 2 M) and 200 ml ethanol are refluxed for 4 hours.: The solution is cooled to +5°C and gradually added 8 g of NaBH^ and then stir for 12 hours at room temperature. The solvent is evaporated and the residue is diluted with 200 ml of water and extracted with ether. An ethereal phase is dried over MgSQ^, filtered and, after passing through dry gaseous HCl, 35 g of III is obtained which is recrystallized from methanol-acetone. • -Melting point: 230-232 oC. Analysis: % Calculated: C 63.39; :H 9.52; N 3.89;
% Funnet: -C 63,70; H 9,75; ■ N 3,85. % Found: -C 63.70; H 9.75; ■ N 3.85.
Eksempel 34 Example 34
1-( 3- metyl-4- metyltiofenyl)- 2- n- oktylaminoetano1 (CP 365 S) 1-( 3- methyl-4- methylthiophenyl)- 2- n- octylaminoethano1 (CP 365 S)
260 g - 3-met<y>l-4-jnet<y>ltio-a-brQmacetof enon., 150 ml n-oktylamin og 500 ml metanol 'tilbakelopsbehandles under omroring i 1 time. Man kjoler av blandingen til oa. 5°C og tilsetter etterhvert en opplosning av 37 g NaBH^ i 12o ml vann pg 3 ml 8N NaOH. Etter tilsetning rorer man-om-over natten ved vanlig temperatur og fordamper opplosningsmidlet. 260 g - 3-meth<y>1-4-jnet<y>ltio-a-brQmacetof enone., 150 ml of n-octylamine and 500 ml of methanol are refluxed with stirring for 1 hour. The mixture is dressed for other purposes. 5°C and gradually adds a solution of 37 g of NaBH^ in 120 ml of water and 3 ml of 8N NaOH. After addition, one stirs overnight at ordinary temperature and evaporates the solvent.
Til resten tilsetter man 50 ml 8N NaOH,og man ekstraherer 3 ganger med 200 ml eter. Den organiske fase vaskes suksessivt med en vandig opplosning av natr ium-kalium-tar t-rat., en vandig opplosning av -NaCl og deretter med vann. Man torker over MgSO^ og filtrerer. Til den -oppnådde eteriske opplosning tilsetter man 130 ml av en opplosning av HCl -2,5 M i eter. Add 50 ml of 8N NaOH to the residue and extract 3 times with 200 ml of ether. The organic phase is washed successively with an aqueous solution of sodium-potassium tar t-rat., an aqueous solution of -NaCl and then with water. It is dried over MgSO^ and filtered. 130 ml of a solution of HCl -2.5 M in ether is added to the -obtained ethereal solution.
Fellingen filtreres, vaskes med aceton og omkrystalliseres fra en blanding av isopropanol og metyletylketon The precipitate is filtered, washed with acetone and recrystallized from a mixture of isopropanol and methyl ethyl ketone
Man får på denne måte _205 g ay hydrokloridet av .1— (3-rnetyl- 4-metyltiofenyl)-2-n-oktylaminoetanol. Smeltepunkt: 198-200°C. Analyse: In this way, _205 g of the hydrochloride of .1-(3-methyl-4-methylthiophenyl)-2-n-octylaminoethanol is obtained. Melting point: 198-200°C. Analysis:
% Beregnet: C 62,50; H 9,30; H 4,05 % Calculated: C 62.50; H 9.30; H 4.05
% Funnet: C 62,42; H 9,40; H 4,10 1 Den tidligere omtalte tabeller, som vedrbrer forbindelser framstilt på samme måte som de forbindelser som er behandlet detaljert i forestående eksempler, vises nedenfor som tabell I og II. % Found: C 62.42; H 9.40; H 4,10 1 The previously mentioned tables, which relate to compounds prepared in the same way as the compounds treated in detail in the forthcoming examples, are shown below as tables I and II.
Tabell I viser forbindelser med den generelle formel I, .hvor R3 og R. betegner hydrogenatom, mens tabell II viser forbindelser, hvor R^ 'og/eller R^ ikke betegner hydrogen. Tabell VI viser forbindelser, hvor R2 = R^ = H og tabell VII viser farmakologiske resultater for forbindelsene ifolge tabell VI. Table I shows compounds of the general formula I, where R 3 and R 1 denote a hydrogen atom, while Table II shows compounds where R 1 and/or R 1 do not denote hydrogen. Table VI shows compounds, where R 2 = R 2 = H and table VII shows pharmacological results for the compounds according to table VI.
jHeretter angis en hel del farmakologiske resulteter for produkter ifolge oppfinnelsen, sammenlignet med kjente produkter. LD^0-verdien ble erholdt ifolge Campbell og Richters teknikk (Acta pharmacol,. et toxicol. 1967, 25, 345). A number of pharmacological results for products according to the invention, compared with known products, are given below. The LD 0 value was obtained according to the technique of Campbell and Richter (Acta pharmacol. et toxicol. 1967, 25, 345).
Det er uventet blitt konstatert at 1-(4-isopropyltiofenyl)-2-n-oktylaminopropanol (CP 556S) har en storre grad av aktivitet enn 1-(4-isopropyltio-3-metyl}fenyl-2-n-oktylaminopropanol (b) og enn 1-(4-isoprdpyltiofenyl)-2-n-oktylaminoetanol (c) hva angår periferisk vasodilatorisk aktivitet.. It has unexpectedly been established that 1-(4-isopropylthiophenyl)-2-n-octylaminopropanol (CP 556S) has a greater degree of activity than 1-(4-isopropylthio-3-methyl}phenyl-2-n-octylaminopropanol (b ) and than 1-(4-isopropylthiophenyl)-2-n-octylaminoethanol (c) in terms of peripheral vasodilatory activity..
Disse erkjennelser er basert på tabell VIII som folger nedenfor: These findings are based on Table VIII which follows below:
I de etterfolgende tabeller IX og X er vist ytterligere sammenligning seksempler mellom dsen terapeutiske aktivitet for forbindelser i henhold til oppfinnelsen og kjente forbindelser, og i tabell IX er gjengitt en sammenligning mellom de fblgende forbindelser: In the following tables IX and X, further comparisons of six examples are shown between the therapeutic activity of compounds according to the invention and known compounds, and in table IX a comparison between the following compounds is reproduced:
CP 236 S = 1-(4-metyltiofenyl)-2-isopropylaminoetanol CP 236 S = 1-(4-methylthiophenyl)-2-isopropylaminoethanol
CP 237 S = hydroklorid av CP 236 S CP 237 S = Hydrochloride of CP 236 S
CP 240 S = 1(3-metyl-4-metyltiofenyl)-2-isopropylaminoetanol CP 366 S = 1-(3-metyl-4-isopropyltiofenyl)-2-n.oktylamino-etanol CP 240 S = 1(3-methyl-4-methylthiophenyl)-2-isopropylaminoethanol CP 366 S = 1-(3-methyl-4-isopropylthiophenyl)-2-n.octylaminoethanol
CP 365 S = 1-(3-metyl-4-metyltiofenyl)rr2-n.oktylaminoetanol. CP 365 S = 1-(3-methyl-4-methylthiophenyl)rr2-n.octylaminoethanol.
hvorav de to forstnevnte er kjente forbindelser. of which the two former are known compounds.
I den etterfolgende tabell XI er det vist sammenlignende aktivitet for to kjente forbindelser, nemlig CP 527 S og CP 237 S, og en spesielt foretrukket forbindelse som fremstilles i henhold til foreliggende oppfinnelse, nemlig.CP 556 S [vi- (4-isopropyltiofenyl)-2-n-oktylaminopropanol] j Perifer-~ vasodllatori sk. aktivitet i.- In the following table XI, comparative activity is shown for two known compounds, namely CP 527 S and CP 237 S, and a particularly preferred compound which is produced according to the present invention, namely CP 556 S [vi-(4-isopropylthiophenyl) -2-n-octylaminopropanol] j Peripheral-~ vasodllatori sk. activity in.-
Betegnelser, O = ikke aktiv Designations, O = not active
+ - lav aktivitet " "- + - low activity " "-
++ = middels aktivitet ++ = medium activity
+++ = virkning er lik virkningen for papavérin +++ = effect is similar to the effect of papaverine
(30 mcg/kg intra-arterielt) r-++++ = virkning overlegen virkningen for ~ (30 mcg/kg intra-arterial) r-++++ = effect superior to the effect for ~
papaverin. papaverine.
B- lvtisk aktivitet. B- lvtic activity.
Aktivitet for 1 dose på 1.10-6 g/ml produkt. Activity for 1 dose of 1.10-6 g/ml product.
Betegnelse: O = hemning av den kronotrope effekt av 1,10 — 8g/ml noradrenalin < 50% Designation: O = inhibition of the chronotropic effect of 1.10 — 8g/ml norepinephrine < 50%
+ - hemning av den kronotrope effekt av 1,10 _7g/- + - inhibition of the chronotropic effect of 1.10 _7g/-
ml noradrenalin < 50% ml norepinephrine < 50%
++ - hemning av den kronotrope.effekt av l,10~<6>g/- ++ - inhibition of the chronotropic effect of l.10~<6>g/-
ml noradrenalin <. 75% ml norepinephrine <. 75%
Antispasmodisk aktivitet; Antispasmodic activity;
lav hemning (+) low inhibition (+)
delvis hemning (+) partial inhibition (+)
fullstendig hemning (++) complete inhibition (++)
ved en bestemt dose antagonist, kontraksjoner ved histamin, acetylcholin Og BaCl2 eller ved lavare doser av et multipel av tre (+++). at a specific dose of antagonist, contractions by histamine, acetylcholine and BaCl2 or at lower doses by a multiple of three (+++).
j I det etterfolgende er vist ytterligere terapeutiske data j for en del av de spesielt foretrukkede forbindelser som fremstilles ifolge foreliggende oppfinnelse, nemlig: CP 422 S; 1-(2-klor-4-metyltibfenyl)-2-N-piperidinoetanol-hydroklorid In the following, additional therapeutic data are shown for some of the particularly preferred compounds produced according to the present invention, namely: CP 422 S; 1-(2-Chloro-4-methyltibphenyl)-2-N-piperidinoethanol hydrochloride
CP 545 S: 1-(3-klor-4-metyltiofenyl)-2-sek.-butylaminopentanol-hyd roki ori d CP 545 S: 1-(3-Chloro-4-methylthiophenyl)-2-sec-butylaminopentanol-hydroxy ori d
CP 453 S; 1- (3-metyl-4-isopropyltibfenyl)-2-n.oktylaminopropanol-hydroklorid CP 453 S; 1-(3-methyl-4-isopropyltibphenyl)-2-n-octylaminopropanol hydrochloride
CP 556 S; 1-(4-isopropyltiofenyl)-2-n-oktylaminopropanol CP 556 S; 1-(4-isopropylthiophenyl)-2-n-octylaminopropanol
CP 365 S; 1-(3-metyl-4-metyltiofenyl)-2-n.oktylaminoetanol-hydroklorid CP 365 S; 1-(3-methyl-4-methylthiophenyl)-2-n.octylaminoethanol hydrochloride
CP 579 S; 1-(4-etyltiofenyl)-2-r .tylairiinopropanol-hydroklorid CP 579 S; 1-(4-Ethylthiophenyl)-2-r.tylarinopropanol hydrochloride
CP 240 S; 1-(3-metyl-4-metyltiofenyl)-2-isopropylaminoetanol-hydroklorid. CP 240 S; 1-(3-methyl-4-methylthiophenyl)-2-isopropylaminoethanol hydrochloride.
som er sammenlignet med de kjente forbindelser "A", "B" og "C", omtalt på side 3 i foreliggende beskrivelse. which is compared with the known compounds "A", "B" and "C", discussed on page 3 of the present description.
Symboler anvendt i tabellene XII - XIV Symbols used in tables XII - XIV
Vasodilasjon: Vasodilation:
O: ikke aktivitet O: no activity
+: meget lav aktivitet +: very low activity
++: ca. halvparten av papaverins aktivitet +++: aktivitet lik papaverins ++: approx. half the activity of papaverine +++: activity equal to papaverine
++++: -aktivitet som overgår papaverins. ++++: -activity surpassing that of papaverine.
Antispasmodisk aktivitet: Antispasmodic activity:
0: ikke aktivitet med 15 ug/ml konsentrasjon +_:_: , svak inhibering av spasmogenenes respons ved 15 ^g/ml 0: no activity at 15 µg/ml concentration +_:_: , weak inhibition of the spasmogen response at 15 µg/ml
konsentrasjon concentration
+: delvis inhibering av spasmogenenes respons ved 15 p<g>/ ml +: partial inhibition of the spasmogenic response at 15 p<g>/ml
konsentrasj on concentration on
++: total inhibering av spasmogenenes respons ved 15 ug/ml konsentrasjon; dette nivå av antispasmodisk aktivitet tilsvarer papaverins ++: total inhibition of the spasmogenic response at 15 ug/ml concentration; this level of antispasmodic activity corresponds to that of papaverine
+++: total inhibering av spasmogens respons ved 5 ug/ml konsentrasjon +++: total inhibition of the spasmogen response at 5 ug/ml concentration
I ++++: total inhibering av spasmogens respons med. 1,5 ug/ml ■ I ++++: total inhibition of the spasmogen's response with. 1.5 ug/ml ■
konsentrasjon. v concentration. v
t t
[ 3- blokkerings- aktivitet [ 3- blocking activity
O: inhibering av den kronotrope effekt på 1,10~ —8g/ml av O: inhibition of the chronotropic effect of 1.10~ —8g/ml of
norepinephrin mindre enn 50%_7 norepinephrine less than 50%_7
+: inhibering av den kronotrope effekt på 1,10 g/ml av +: inhibition of the chronotropic effect of 1.10 g/ml of
norepinephrin mindre enn 50%. norepinephrine less than 50%.
++: inhibering av den kronotrope effekt på 1,10<->^ g/ml av norepinephrin mindre, enn 75% -5 ++: inhibition of the chronotropic effect of 1.10<->^ g/ml of norepinephrine less than 75% -5
+++: inhibering av den kronotrope effekt på 1,10 g/ml av +++: inhibition of the chronotropic effect of 1.10 g/ml of
norephrin mer eller til 60 norephrine more or to 60
++++: total inhibering av effektene til disse konsentrasjoner av norepinephrin. Dette er aktivitetsnivået til propranolol, en standard [3-blokkerer. ++++: total inhibition of the effects of these concentrations of norepinephrine. This is the activity level of propranolol, a standard [3-blocker.
Den etterfolgende tabell XV viser vasodilatorisk virkning i perfusert hundelabb for den spesielt foretrukkede forbindelse CP 556 S og flere k nte periferisk vasodilatoriske virksomme forbindelser, administrert i.a. ved en dose på 30 ug/kg. The following table XV shows vasodilatory action in perfused dog paw for the particularly preferred compound CP 556 S and several known peripherally vasodilator active compounds, administered i.a. at a dose of 30 ug/kg.
Kommentarer til tabellene XII XV Comments on Tables XII XV
Fra tabelleXII kan det ses at forbindelsene CP 453 S og CP From tableXII it can be seen that the compounds CP 453 S and CP
556 S utviser betydelig bedre egenskaper enn forbindelsene "A", "B" og "C" med hensyn til deres vasodilatoriske og antispasmodiske egenskaper. Med hensyn til deres vasodilatcriske egenskaper er CP 453 S og CP 556 S meget mer virksomme enn papaverin, en meget velkjent referanseforbindelse, mens "A", "B" og "C" er uaktive eller meget mindre aktive enn papaverin, og kan derfor ikke forventes å ha noen klinisk interesse. Disse forbindelsene "A", "B" og "C" kan normalt ikke betraktes som poten-sielle f orbindelser.. På den annen side er de verdifulle egenskaper for CP 556 S ytterligere blitt underbygget ved å sam-menligne denne forbindelse med andre velkjente forbindelser og i så henseende er CP 556 S funnet å være overlegent bedre enn alle de andre referanse-forbindelser, hvilket fremgår av tabell XV. 556 S exhibits significantly better properties than compounds "A", "B" and "C" with respect to their vasodilatory and antispasmodic properties. With regard to their vasodilator properties, CP 453 S and CP 556 S are much more active than papaverine, a very well-known reference compound, while "A", "B" and "C" are inactive or much less active than papaverine, and therefore cannot expected to have some clinical interest. These compounds "A", "B" and "C" cannot normally be considered as potential compounds. On the other hand, the valuable properties of CP 556 S have been further substantiated by comparing this compound with other well-known compounds. compounds and in this respect CP 556 S is found to be superior to all the other reference compounds, as shown in Table XV.
Med hensyn til antispasmodisk aktivitet utviser igjen CP 453 S og CP 556 S overlegent bedre egenskaper enn forbindelsene "A", With regard to antispasmodic activity, again CP 453 S and CP 556 S exhibit superior properties than compounds "A",
"B" og "C", idet aktivitetsnivået for "A", "B" og "C" er for lavt.til at deres aktivitetsforhold kan beregnes. K6mbinas-jonen av de meget viktige aktiviteter for CP 453 S og CP "B" and "C", as the activity level for "A", "B" and "C" is too low for their activity ratio to be calculated. The combination of the very important activities for CP 453 S and CP
556 S, nemlig vasodilatering og antispasmodisk effekt, er av den storste betydning for deres terapeutiske anvendelse ved blokkerende vaskulær-sykdommer. Det kan også bemerkes med hensyn til CP 556 S at disse konklusjoner allerede er underbygget ved forskjellige kontrollerte kliniske forsok ved claudicatio 556 S, namely vasodilatation and antispasmodic effect, are of the greatest importance for their therapeutic use in obstructive vascular diseases. It can also be noted with regard to CP 556 S that these conclusions have already been substantiated by various controlled clinical trials in claudication
intermittens og ved cerebrovaskulær mangel. F.eks. er CP i 556 S funnet å være overlegent bedre enn placebo, cinnerazin og "Hyde* rgin R!.'. på den: annen side er den adrenergiske (3-blokkerende effekt for forbindelsene "A", "B" og "C", som er fraværende for CP 453 S og CP 556 S, å anse som en uonsket sideeffekt for en slik medisinsk anvendelse. Ytterligere synes toksisiteten for CP 453 S og CP 556 S å være meget svak. intermittent and in case of cerebrovascular insufficiency. E.g. is CP in 556 S found to be superior to placebo, cinnerazine and "Hyde* rgin R!.'. on the other hand, the adrenergic (3-blocking effect for compounds "A", "B" and "C" , which is absent for CP 453 S and CP 556 S, to be considered an undesirable side effect for such medical use.Furthermore, the toxicity of CP 453 S and CP 556 S appears to be very weak.
o o
Fra tabell XIII kan det konkluderes at forbindelsene CP 365 S og CP 579 S er vesentlig bedre enn forbindelsene "A", "B" og "C" med hensyn til deres antihypértensive aktivitet, idet forbindelsene "B" og "C" er fullstendig uten aktivitet, mens forbindelsen "A" er noe aktiv, men utviser også en adrenergisk P-blokkerende effekt, som er uonsket. CP 365 S og CP 579 S er på mg/kg-dosebasis ca. 13 ganger mer effektiv enn metyldopa. De to forbindelsene viser også viktige vasodilatoriske og antispasmodiske egenskaper som kun er meget liten for forbindelsene "A", "B" og "C" som angitt ovenfor, egenskaper som imidlertid er nyttige ved behandling av hyper-tensjon. Det bor også bemerkes at de forste kontrollerte kliniske forsok med CP 365 S underbygger dets viktighet ved kontroll av hypertensive sykdommer hos mennesker. From Table XIII, it can be concluded that compounds CP 365 S and CP 579 S are significantly better than compounds "A", "B" and "C" with respect to their antihypertensive activity, compounds "B" and "C" being completely without activity, while compound "A" is somewhat active, but also exhibits an adrenergic β-blocking effect, which is undesirable. CP 365 S and CP 579 S are on a mg/kg dose basis approx. 13 times more effective than methyldopa. The two compounds also show important vasodilatory and antispasmodic properties which are only very little for the compounds "A", "B" and "C" as indicated above, properties which are however useful in the treatment of hypertension. It should also be noted that the first controlled clinical trials with CP 365 S support its importance in the control of hypertensive diseases in humans.
Fra tabell XIV kan det sluttes at forbindelsene CP 422 S, From Table XIV it can be concluded that the compounds CP 422 S,
CP 454 S og CP 240 S er vesentlig bedre enn forbindelsene "A", "B" og "C" med hensyn til deres beskyttende virkning mot anoxia i hjertemuskelen, idet forbindelsene "B" og "C" ikke utviser noen aktivitet i =å henseende, mens for-bindélsen: "A" var noe aktiv. Det er.også av interesse å bemerke at for CP 240 S er den beskyttende effekt assosiert med en adrenergisk (3-blokkerende effekt, på samme måte som for forbindelse "A" , imidlertid er i denne henseende CP 240 S mer enn 5 ganger så aktiv som forbindelse "A". Kombinasjonen av disse to egenskaper er av teoretisk interesse for behandling- av hjertelidelser som angor. Imidlertid for tilfeller med en tilhorende hjertesvikt er den adrenergiske P-bl-okkerende aktivitet kontra-indikert, og dette forklarer-.interessen for i CP 422 S og 454 S som utviser en beskyttende effekt mot anoxia uten en Ø-blokkerende effekt. CP 454 S and CP 240 S are significantly better than compounds "A", "B" and "C" with respect to their protective action against anoxia in the heart muscle, compounds "B" and "C" showing no activity in respect, while the conjunction: "A" was somewhat active. It is also of interest to note that for CP 240 S the protective effect is associated with an adrenergic (3-blocking effect, in the same way as for compound "A", however, in this respect CP 240 S is more than 5 times as active as compound "A". The combination of these two properties is of theoretical interest in the treatment of cardiac disorders such as angina pectoris. However, for cases with an associated heart failure, the adrenergic P-bl-occlusive activity is contraindicated, and this explains the interest for in CP 422 S and 454 S which exhibit a protective effect against anoxia without an Ø-blocking effect.
Claims (11)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE79767 | 1969-10-01 | ||
BE93537 | 1970-09-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO132865B true NO132865B (en) | 1975-10-13 |
NO132865C NO132865C (en) | 1976-01-21 |
Family
ID=25647478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO3712/70A NO132865C (en) | 1969-10-01 | 1970-09-30 |
Country Status (17)
Country | Link |
---|---|
JP (1) | JPS541693B1 (en) |
AR (1) | AR194457A1 (en) |
AT (1) | AT323135B (en) |
CA (1) | CA953723A (en) |
CH (1) | CH542177A (en) |
CS (1) | CS191158B2 (en) |
DK (1) | DK147853C (en) |
FI (1) | FI52714C (en) |
FR (1) | FR2070102A1 (en) |
HU (1) | HU167354B (en) |
IE (1) | IE34545B1 (en) |
NL (1) | NL156688B (en) |
NO (1) | NO132865C (en) |
OA (1) | OA03659A (en) |
SE (1) | SE384855B (en) |
SU (1) | SU578860A3 (en) |
YU (1) | YU35580B (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1386029A (en) * | 1972-03-20 | 1975-03-05 | Smithkline Corp | Alpha-benzylamino-4-benzyloxy-3-alkylsulphonylmethyl phenones |
DE2862340D1 (en) * | 1978-02-01 | 1983-11-24 | Wellcome Found | Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations thereof |
GB2067187B (en) * | 1979-12-07 | 1983-11-30 | Cosmos Enterprise | Process for the preparation of 1-(4-hydroxyphenyl)-2-(4-benzylpiperidino)-1-propanol and acid addition salts thereof |
FR2503705A1 (en) * | 1981-04-14 | 1982-10-15 | Synthelabo | PHENETHANOLAMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
FR2508445A1 (en) * | 1981-06-29 | 1982-12-31 | Sori Soc Rech Ind | NOVEL BENZOYL-PHENYL-PIPERIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR USE, IN PARTICULAR THERAPEUTICS |
FR2534580A1 (en) * | 1982-10-13 | 1984-04-20 | Synthelabo | PHENYL-1 PIPERIDINO-2 PROPANOL DERIVATIVES, THEIR PREPARATION, AND MEDICINES THAT CONTAIN THEM |
FR2537132B1 (en) * | 1982-12-06 | 1987-01-09 | Lafon Labor | NOVEL SULFUR DERIVATIVES OF 2-AMINO-1-PHENYL-1-ETHANOL, USE IN THERAPEUTICS AND METHOD OF PREPARATION |
US5101065A (en) * | 1991-02-04 | 1992-03-31 | Imperial Chemical Industries Plc | Acetophenone intermediates |
FR2741067B1 (en) * | 1995-11-10 | 1997-12-26 | Rhone Poulenc Chimie | PROCESS FOR ACYLATION OF AN AROMATIC THIOETHER |
FR2757160B1 (en) * | 1996-12-13 | 1999-03-12 | Sanofi Sa | 1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES |
GB201714736D0 (en) * | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714734D0 (en) * | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1503517A (en) * | 1965-04-22 | 1967-12-01 | Bayer Ag | Manufacturing process of d - (-) - n-alkyl-1-phenyl-2-aminoethanols |
-
1970
- 1970-09-22 IE IE1225/70A patent/IE34545B1/en unknown
- 1970-09-24 SE SE7012989A patent/SE384855B/en unknown
- 1970-09-28 YU YU2385/70A patent/YU35580B/en unknown
- 1970-09-28 AR AR231509A patent/AR194457A1/en active
- 1970-09-30 AT AT885270A patent/AT323135B/en not_active IP Right Cessation
- 1970-09-30 NO NO3712/70A patent/NO132865C/no unknown
- 1970-09-30 FI FI702661A patent/FI52714C/en active
- 1970-09-30 DK DK497870A patent/DK147853C/en not_active IP Right Cessation
- 1970-09-30 CA CA094,617A patent/CA953723A/en not_active Expired
- 1970-09-30 CS CS706633A patent/CS191158B2/en unknown
- 1970-10-01 SU SU7001482607A patent/SU578860A3/en active
- 1970-10-01 FR FR7035552A patent/FR2070102A1/en active Granted
- 1970-10-01 CH CH1452070A patent/CH542177A/en not_active IP Right Cessation
- 1970-10-01 JP JP8561070A patent/JPS541693B1/ja active Pending
- 1970-10-01 NL NL7014444.A patent/NL156688B/en not_active IP Right Cessation
- 1970-10-01 HU HUPA1078A patent/HU167354B/hu unknown
- 1970-10-02 OA OA54048A patent/OA03659A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AT323135B (en) | 1975-06-25 |
DK147853B (en) | 1984-12-24 |
YU35580B (en) | 1981-04-30 |
SE384855B (en) | 1976-05-24 |
SU578860A3 (en) | 1977-10-30 |
CS191158B2 (en) | 1979-06-29 |
DK147853C (en) | 1986-05-20 |
NL7014444A (en) | 1971-04-05 |
AR194457A1 (en) | 1973-07-23 |
IE34545B1 (en) | 1975-06-11 |
FR2070102B1 (en) | 1974-08-23 |
FI52714B (en) | 1977-08-01 |
NO132865C (en) | 1976-01-21 |
YU238570A (en) | 1980-09-25 |
FI52714C (en) | 1977-11-10 |
HU167354B (en) | 1975-09-27 |
JPS541693B1 (en) | 1979-01-27 |
NL156688B (en) | 1978-05-16 |
CA953723A (en) | 1974-08-27 |
IE34545L (en) | 1971-04-01 |
OA03659A (en) | 1971-12-24 |
FR2070102A1 (en) | 1971-09-10 |
CH542177A (en) | 1973-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3954871A (en) | 1-(4-Alkylthiopheny)-2-substituted amino-alcohols and their salts | |
Poos et al. | 2-Amino-5-aryl-2-oxazolines. Potent new anorectic agents | |
US6660756B2 (en) | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | |
CA2437113A1 (en) | N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad | |
NO132865B (en) | ||
NO153220B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE IMIDAZOLINE DERIVATIVES | |
DK145260B (en) | METHOD OF ANALOGUE FOR THE PREPARATION OF 4-ACYLAMINO-PHENYL-ETHANOLAMINES OR ACID ADDITION SALTS | |
Howe et al. | . beta.-Adrenergic blocking agents. I. Pronethalol and related N-alkyl and N-aralkyl derivatives of 2-amino-1-(2-naphthyl) ethanol | |
NO161543B (en) | EXPLOSION CHARGING FOR USE IN THE EXPLOSION WELDING OF PUTS. | |
US3933913A (en) | N,N'-bis[3-substituted-4-hydroxypheyl)-2-hydroxyethyl)]-polymethylenediamines | |
Lunsford et al. | 5-Aryloxymethyl-2-oxazolidinones | |
US4443449A (en) | Arylcyclobutylalkylamines and anti-depression composition and methods using same | |
US3700692A (en) | 1-(4{40 -hydroxy-3{40 -(hydroxy methyl)-phenyl)-1-hydroxy-2-aralkylaminoethanes | |
US3255249A (en) | 2-branched lower alkyl-amino-1-(indan-, hydrogenated indan- and hydrogenated naphth-2-yl) lower alkanols | |
MOFFETT et al. | SUBSTITUTED PYRROLIDINES AND PYRROLIDYLETHANOLS1 | |
NO126914B (en) | ||
US2938921A (en) | Nu-[beta-(3, 4-dichlorophenyl)-beta-hydroxyethyl] isopropylamine and salts | |
FUJIKURA et al. | Studies on Benzenesulfonamide Derivatives with α-and β-Adrenergic Antagonistic and Antihypertensive Activities | |
US3943173A (en) | 3-Alkylamino- alpha-aminomethyl-4-hydroxybenzyl alcohols | |
NO115028B (en) | ||
Burger et al. | Amino Derivatives of 2, 2-Diphenylcyclohexanone. I1 | |
US4104402A (en) | 5,6-Dihydroxy aminotetralol compounds | |
US3786154A (en) | Compositions and method employing 1-(4-hydroxy-3'-(hydroxymethyl)-phenyl)1-hydroxy-2-aralkylaminoethanes | |
BE739678A (en) | 1 subst phenyl 2 amino ethanols useful as beta - adrenergic agents peripheral vasodilators and hypo- | |
US4358460A (en) | Substituted 3-aryl-2-cycloalken-1-one and method of preparation thereof |